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ABSTRACT 
 
Diabetes mellitus (DM) or diabetes, a common metabolic disorder distinctively characterised 
by hyperglycemia, is a major non-communicable disease that affects millions of people 
globally, resulting in high incidences of morbidity and premature death rates. Chronic 
complications associated with DM include neuropathy, retinopathy, nephropathy and 
atherosclerosis. The management of diabetes has proven challenging especially in developing 
countries, due to costly ongoing treatments and often inaccessible health facilities. Due to the 
side effects and costs associated with current diabetes treatments, there is an upsurge in 
research into new antidiabetic agents specifically produced by plants.                                                                                      
In the present investigation four plant species, selected based on their traditional medicinal uses 
to treat diabetes, were subjected to a number of ethnopharmacological tests to validate their 
efficacy and to discover possible bioactive chemicals. Plant extracts were evaluated for their 
ability to inhibit enzymes involved in diabetes including α-amylase and α-glucosidase. Since 
oxidative stress and infections contribute greatly to complications related to diabetes, 
antioxidant and antimicrobial screening assays were performed and to further evaluate the 
safety of the plant extracts, mutagenic screenings were carried out. The extracts were also 
subjected to phytochemical analysis to evaluate the presence of secondary metabolites which 
are believed to form the basis of the bioactivities observed in plants.  
The different plant specimens (Bulbine natalensis, Kigelia africana, Leonotis leonurus and 
Sclerocarya birrea) were collected from different locations; Mkhabathini farm KwaZulu-
Natal, Ga-Mothapo village and the University of KwaZulu-Natal Botanical Garden, from 
March to April 2018. A voucher specimen for each species was deposited at the Herbarium of 
the University of KwaZulu-Natal, Pietermaritzburg. The dried plant materials were ground 
independently and extracted using different solvents of varying polarities (Petroleum ether, 
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Dichloromethane, Acetone and water). The resulting 24 extracts were evaluated for 
antidiabetic, antimicrobial and antioxidant activities. Fifty percent aqueous methanol extracts 
were subjected to phytochemical analysis. 
The plant extracts were exposed to different free radical systems to observe their scavenging 
abilities. The extracts were subjected to in vitro heat induced β-Carotene oxidation, 1-1- 
diphenyl-1-picryhydrazyl (DPPH), hydrogen peroxide (H2O2) and ferric cyanide (Fe
3+) 
reducing antioxidant power (FRAP) screenings. The β-Carotene antioxidant activity was 
higher for ACE and water extracts of the stem bark of S. birrea. However, the PE extracts of 
both the leaf of L. leonurus and stem bark of S. birrea displayed no β-Carotene bleaching 
activity. The oxidation rate ratio was lower for ACE extract of the stem bark of S. birrea (0.05) 
than butylated hydroxyltoluene (BHT). The DPPH radical scavenging activity was higher in 
water and ACE leaf and root extracts of B. natalensis, DCM and water leaf extracts, ACE and 
water extracts of the fruit of K. africana, DCM, ACE and water extracts of leaves of L. leonurus 
and ACE and water extracts of S. birrea stem bark.  The lowest IC50 was shown by ACE extract 
of fruit of K. africana and a water extract of the leaf of L. leonurus (0.01 mg/mL). The ability 
of the extracts to reduce H2O2 to water was better demonstrated by the ACE extract of roots of 
B. natalensis; water extract of fruit from K. africana, as well as ACE and water extracts of S. 
birrea stem bark. The ferric reducing power was better demonstrated by a PE extract of the 
fruit of K. africana; DCM leaf extract of L. leonurus and also ACE and water extracts of S. 
birrea stem bark. Extracts exhibiting weakest reducing power at the highest concentrations 
tested (12.5 mg/mL) were PE and DCM extracts of S. birrea stem bark; ACE leaf extract of K. 
africana and water extract of leaves of B. natalensis. 
Preliminary phytochemical screening revealed the presence of flavonoids, alkaloids and 
carbohydrates for all plant extracts. The absence of certain classes of secondary metabolites 
during screening were observed in leaves of B. natalensis (phenols, terpenoids, tannins and 
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steroids), fruit of K. africana (phenols and steroid) and leaves of K. africana (steroids). The 
spectrophotometric phytochemical analysis revealed the quantities of some secondary 
metabolites (total phenolic content, flavonoids and condensed tannins) in the plant species. The 
stem bark of S. birrea exhibited the highest total phenolic content (41,21 mg GAE/g), 
flavonoids (175,78 mg CE/g) and condensed tannins (1,91 mg CCE/g). Roots of B. natalensis 
showed the lowest phenolic content (5,31 mg GAE/g) and leaves of K. africana had low levels 
of both flavonoids and condensed tannins (30,08 mg CE/g and 0.14 mg CCE/g, respectively).  
The antidiabetic inhibitory screening of the α-amylase and α-glucosidase enzymes revealed the 
potentials of the different plant extracts to act as natural antidiabetic agents. A modified 
microtitre plate technique was used to evaluate the α-glucosidase inhibitory activity, while a 
modified DNSA (3.5-dinitrosalicyclic acid solution) method was used to evaluate the α-
amylase inhibitory activity of the plant extracts at 100 µg/mL. High α-amylase inhibitory 
activity was observed in DCM and water extracts of leaf extracts of B. natalensis, ACE extract 
of leaves of L. leonurus and water extracts of leaves of K. africana and S. birrea stem bark. 
Potent α-glucosidase inhibitory activity was shown by DCM and ACE extracts of roots of B. 
natalensis, ACE extracts of leaves of B. natalensis, ACE extracts of fruit of K. africana and 
ACE and water extracts of S. birrea stem bark. Better antidiabetic activities were exhibited by 
the organic extracts as compared to the water extracts. 
For antimicrobial screening, test organisms from the American Type Culture Collection 
(ATCC) were used to evaluate the ability of plant extracts to inhibit pathogenic bacteria. Gram-
positive (Enterococcus faecalis, ATCC 19433 and Staphylococcus aureus, ATCC 12600) and 
Gram-negative (Escherichia coli, ATCC 11775 and Klebsiella pneumoniae, ATCC 13883) and 
the yeast Candida albicans (ATCC 10231) strains were used for this investigation. The 
microplate dilution technique was adopted to determine the minimum inhibitory concentration 
(MIC) of the extracts. High antimicrobial inhibitory activity against both the antibacterial and 
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antifungal strains was demonstrated by the DCM extract of roots of B. natalensis, ACE and 
water extract of S. birrea stem bark and ACE extracts of leaves of L. leonurus (MIC < 1 
mg/mL). However, the DCM extract of leaves of B. natalensis and the ACE extract of roots of 
B. natalensis did not display effective microbial inhibitory activity against all bacterial strains 
tested (MIC > 1 mg/mL).  
The plant extracts demonstrating complimentary antidiabetic inhibitory activities against α-
amylase and α-glucosidase, were selected and further subjected to the Ames test using tester 
organisms (TA 102 and 1535) without the S9 metabolic activation, to evaluate their safety. All 
tested extracts did not display mutagenicity toward the tester organisms. However, the ACE 
extract of the stem bark of S. birrea displayed some potential to become mutagenic. These 
findings emphasise the importance of investigating the safety of natural products consumed for 
medicinal purposes. The obtained information further validates the traditional use of these 
medicinal plants as antidiabetic medicines and provides a valuable opportunity to discover 
potential sources of novel treatments against the carbohydrate hydrolysing enzymes to alleviate 
or prevent DM. 
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CHAPTER ONE: INTRODUCTION AND LITERATURE 
REVIEW 
1.1  Introduction 
 
Humanity has always been susceptible to diseases caused by pathogens or as a consequence of 
aging (ARMELAGOS et al., 1996). To date, communicable and non-communicable diseases 
have had devastating impacts worldwide. Communicable diseases are responsible for high 
levels of morbidity and mortality globally (SAKER et al., 2004; WHO, 2010). For example, 
the global burden of disease study (GBDS) reported that in 2002, communicable diseases 
contributed to approximately 52% of deaths in developing countries (WHO, 2008). The 
epidemics and pandemics of communicable diseases have caused overwhelming health and 
socio-economic consequences especially in low income countries where the burden of these 
diseases is higher than in other countries (SAKER et al., 2004; WHO, 2010). However, amid 
all these health issues, non-communicable diseases (NCDs) are now competing with 
communicable diseases, adding to morbidity and premature mortality rates higher than those 
caused by infectious diseases (SAKER et al., 2004). The burden of non-communicable 
diseases can be catastrophic in developing countries, where there are higher incidents of 
communicable diseases, limited health facilities in addition to exhausted health budgets and 
poverty (MAYOSI et al., 2009; BOUTAYEB and BOUTAYEB, 2005). Alarmingly, 
according to the World Health Organisation (WHO), in South Africa the burden of non-
communicable diseases is three-fold higher than in developed countries (MAYOSI et al., 
2009). 
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1.2  Non-communicable diseases (NCDs) 
 
Non-communicable diseases (NCDs) are not only a worldwide burden but are a major public 
health concern, challenging social and economic development globally (WHO, 2018). There 
are several causes of NCDs including genetics, environmental and behavioural constituents 
(WHO, 2018). Due to the persistent nature of these diseases, they are classified as chronic 
diseases. Major types of NCDs include cardiovascular diseases (CVDs), cancers, chronic 
respiratory diseases and diabetes mellitus (WHO, 2018). NCDs are the primary cause of 
premature mortality globally and account for over 80% of deaths in low and middle-income 
countries (MISGANAW et al., 2014; WHO, 2018). 
At present, the population of the African continent is predominantly affected by infectious 
diseases such as Human immunodeficiency virus/ Acquired immunodeficiency syndrome 
(HIV/AIDS) and Tuberculosis (TB) (WHO, 2018). However, the World Health Organisation 
(WHO) has suggested that by the year 2030, NCDs will become major causes of death in the 
region (WHO, 2018). For example, in South Africa the Burden of Disease Research Unit at 
the South African Medical Research Council reported that NCDs are the leading cause of death 
in South Africa (SA) surpassing the rates of mortality caused by HIV/AIDS and TB combined 
(NOJILANA et al., 2016; WHO 2013).  
1.3  Diabetes mellitus 
 
Diabetes mellitus (DM) is considered to be one of the four major non-communicable diseases 
worldwide (WHO, 2016). DM is a metabolic disorder that results from a deficiency in the 
production and/or utilisation of insulin (MARITIM et al., 2003). Hyperglycemia, an increase 
in blood glucose levels, is a common trait of diabetes and causes a disruption in functioning of 
proteins, fats and carbohydrates (BILAL et al., 2018; GOBOZA et al., 2016). DM is a global 
concern affecting all population classes and races, and as such, has become one of the most 
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important global health challenges (BILAL et al., 2018; WHO, 2016). Diabetes occurs in 
either of three forms; Type 1; Insulin Dependent Diabetes Mellitus (IDDM) resulting from a 
complete deficiency of insulin caused by the immunological destruction of the pancreatic β-
cells. Type 2; Non-Insulin Dependent Diabetes Mellitus (NIDDM) triggered by limited insulin 
production from the pancreatic β-cells (GOBOZA et al., 2016). Type 3; gestational diabetes 
which occurs during pregnancy because of dysglycemia (McDONALD, 2008). 
Generally, DM is initiated by hypoglycemic conditions in the body and insulin resistance by 
targeted cells. DM is one of the apparent causes of increased morbidity and mortality 
worldwide (GOBOZA et al., 2016; WHO, 2016). The development of DM can also be 
attributed to external factors such as environmental conditions and the intake of certain food 
products that can lead to the mutation of immunological cells through the destruction of β-cells 
(HNATYSZYN et al., 2002; CUEVAS et al., 2008). The use of steroids can also trigger the 
development of diabetes (FERNER, 1992). 
1.3.1 Classification and pathogenesis of Diabetes mellitus 
 
A classification system is of utmost importance to allow for better control of diabetes. Based 
on the old classification system developed by an Expert Committee in 1980 two main types of 
DM were proposed; 1) Insulin Dependent Diabetes Mellitus (IDDM) known as Type 1 DM 
(Figure 1.1) and 2) Non-Insulin Dependent Diabetes mellitus (NIDDM) known as Type 2 DM 
(Figure1.2) (DEFRONZO et al., 2015; WHO, 2016). However, in the 1985 Study Group 
Report, the categorisation of Type 1 and Type 2 were excluded and only categories of IDDM 
and NIDDM were maintained. Moreover, a new class, known as ‘Malnutrition-related Diabetes 
mellitus’ (MRDM) was introduced, however it is no longer part of the WHO classification 
guide (BILAL et al., 2018; DEFRONZO et al., 2015; WHO, 2016). This classification 
system was, however, considered misleading as the diagnosis was categorised on the basis of 
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the patients’ need for insulin and age instead of pathological processes. Considering the 
limiting factors of this system the World Health Organisation proposed a new classification 
system from which active etiological factors and not pharmacological therapies are considered 
prior to diagnosis (O’RAHILLY, 1998; WHO, 2016). Furthermore, from the 1980 and 1985 
reports, numerous categories of diabetes comprised of other types such as Gestational DM 
(GDM) and Monogenic diabetes syndromes (MODY), a type of NIDDM, occurring as an effect 
of autosomal-dominant inheritance that cause insufficient insulin secretion (BASTAKI, 2005; 
JAIN, 2012; ADA, 2018) were recorded. At present Type 1 and Type 2 are terms commonly 
used to respectively depict IDDM and NIDDM (BASTAKI, 2005). 
1.3.1.1 Type 1 Diabetes mellitus (T1DM) 
 
Figure 1. 1: Illustration of the pathogenesis of Type 1 Diabetes mellitus. Image retrieved 
from: http://digitalprinthouses.com/type-1-diabetes-type-1-diabetes/  
 
Occasionally referred to as Juvenile diabetes, T1DM is an autoimmune disease of the β-cells 
responsible for the production of insulin in the body and can develop at any age (BASTAKI, 
2005; GARG, 2011; DEFRONZO et al., 2015). The destruction of the β-cells causes absolute 
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deficiency in insulin. This is known as ‘idiopathic’ of which the cause and pathologic processes 
are not known. This form is mostly common in African and Asian aboriginals (KERNER and 
BRÜCKEL, 2014; DEFRONZO et al., 2015).  
The forms of T1DM are clinically known as Type 1a, which occurs due to insufficient insulin 
due to the impairment of the pancreatic β-cells and  affects 90% of Type 1 patients and Type 
1b is considered idiopathic and affects 10% of Type 1 diabetes patients, respectively 
(BASTAKI, 2005; ACHENBACH and ZIEGLER, 2005; WASSERFALL and 
ATKINSON, 2006). Currently, the exact cause of T1DM is still not clear, however, it has been 
associated with a number of factors such as genetics and environmental factors (THEBERGE, 
2010). T1DM contributes to approximately 10% of diabetes cases (BILAL et al., 2018; 
GARG, 2011). Some of the symptoms of T1DM may occur occasionally and include 
dehydration (polydipsia), frequent urination (polyuria), bulimia, weight loss, change in vision 
and fatigue (DEFRONZO et al., 2015; WHO, 2016). 
1.3.1.2 Type 2 Diabetes mellitus (T2DM) 
 
Figure 1. 2: Illustration of the pathogenesis of Type 2 Diabetes mellitus. Image retrieved 
from: http://www.health.am/db/more/risk-for-type-2-diabetes/  
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T2DM, sometimes referred to as adult-onset diabetes, is mainly observed in adults although a 
few incidences do occur in children (WHO, 2016). T2DM stems from the body’s inability to 
efficiently use insulin produced by β-cells. This could be a result of insulin resistance or lack 
of insulin sensitivity from target cell receptors (WHO, 2016; GOBOZA et al., 2016). This 
type of diabetes occurs frequently in obese or overweight individuals, however, in this regard 
obesity is seen as a phenotypic expression and not necessarily a symptom of diabetes. For 
instance, in South Africa, studies have shown that about 87% of T2DM individuals are obese. 
Obesity has been regarded as an instigator for T2DM. Other factors contributing to the 
progression of T2DM include age and the use of antiretroviral therapy (ARVs) (KERNER and 
BRÜCKEL, 2014; GOBOZA, 2016; WAUGH et al., 2007).  
T2DM is very common and a larger number of incidents occur in urban rather than rural areas 
(BASTAKI, 2005). However, in southern Africa, the incidence of T2DM has started to 
increase in rural areas and this could be due to genetic defects, life style changes such as the 
lack of exercise, dietary changes, as well as obesity amongst individuals (MICHAEL et al., 
2000; BASTAKI, 2005; GOBOZA et al., 2016; NASRI et al., 2015). Typically, the 
symptoms of T2DM may mimic those of T1DM prior to complications related to T2DM which 
then arise (WHO, 2016).  
1.3.1.3 Gestational diabetes (GDM) 
 
GDM occurs as a result of increased blood glucose levels during pregnancy in women without 
a history of prior diabetes diagnosis (NASRI et al., 2015). This form of diabetes appears for a 
short-term period and it is diagnosed during prenatal care. Women who have gestational 
diabetes have about a 50% chance of acquiring T2DM in future (BASTAKI, 2005; 
BELLAMY et al., 2009; WHO, 2016). GDM increases complications during pregnancy and 
delivery and these complications amongst others are associated with the observed acute foetal 
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birth weight (CHINSEMBU, 2018; WHO, 2016). This form of diabetes occurs approximately 
in 4-10% of all pregnancies (BASTAKI, 2005; NDC, 2011).   
 
1.3.2 Diagnosis of DM 
 
Based on the International Expert Committee (IEC) report of 1997, there is a set of criteria 
used in the diagnosis of diabetes. These include indications of increased blood glucose levels 
also called plasma glucose criteria. For instance: 
• Fasting glucose levels are ≥126 mg/dL or a casual glucose level >11.1 mmol/L are 
identified (PANINI, 2013; IEC, 2009).  
• The 75 g oral glucose tolerance test (OGTT) which is performed through the 2 h plasma 
glucose (2 h PG), (GREENBERG and SACKS, 2002, IEC, 2009).  
•  The airman first class (A1C) criteria from which a test is performed using a 
standardised National Glycohaemoglobin Standardization Program (NGSP) certified 
method; known as the Diabetes Control and Complications Trial (DCCT) assay (ADA, 
2018).  
During pregnancy, gestational diabetes can be diagnosed using the following criteria; the “One-
step” approach of 75 g OGTT or the “Two-step” approach with a 50 g (non-fasting) screening 
followed by a further 100 g OGTT screening for those who screened positive (ADA, 2018). 
Due to a number of complications associated with DM the National Diabetes Data Group 
(NDDG) proposed criteria for diagnosing DM (ADA, 2009), based on:  
• Epidemiological data, related to blood glucose levels  
• Detected microvascular complications  
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1.3.3 Symptoms and complications associated with DM 
 
The symptoms for T1DM and T2DM are not too different but the intensity at which they 
present may vary (BASTAKI, 2005). In T1DM, symptoms may occur promptly and are more 
pronounced and this, amongst others, include loss of weight, candidiasis, polyuria (excessive 
urination), polyphagia (intense thirstiness), polydipsia (excessive hunger) and blurred vision 
(COOKE and PLOTNICK, 2008).  
 Most complications develop if diabetes is left untreated or if uncontrollable, can cause life 
threatening conditions (WHO, 2016). These may occur as a result of postprandial 
hyperglycemia, excessive exercise or higher doses of antidiabetic medicine (WHO, 2016). 
High blood glucose levels can initiate malaise such as Diabetic ketoacidosis (DKA) in both 
T1DM and T2DM and can further cause hyperosmolar non-ketonic coma in T2DM sufferers 
(WALLACE, 2004; MOHAN, 2002). Hypoglycemia may occur as a result of extremely low 
blood glucose levels and this can happen to any diabetic individual and may cause seizures or 
unconsciousness (WHO, 2016; WALLACE, 2004; MOHAN, 2002). Prolonged uncontrolled 
diabetes can cause more chronic complications such as diabetic retinopathy (damaged retina) 
and can cause blurred vision or blindness, diabetic neuropathy (damaged nerves) on the feet 
and can cause foot ulcers which may attract infections and lead to limb amputation (Table 1.1). 
Diabetic nephropathy (kidney damage) causes kidney failure and atherosclerosis which may 
lead to strokes and heart attacks (WHO, 2016; WALLACE, 2004; MOHAN, 2002). These 
life threatening complications contribute significantly to health costs, mortality and morbidity 
(WHO, 2016). Some of the GDM complications include congenital deformity, nervous system 
muscle anomalies, maternal disability, respiratory distress syndrome, stillbirth and in severe 
cases, perinatal death (NDC, 2011; WHO, 2016).   
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Table 1. 1: Categorisation of diabetes associated complications (WALLACE, 2004; 
MOHAN, 2002; NASRI et al., 2015). 
Acute complications  Chronic complications 
Infections 
Diabetic ketoacidosis (DKA) 
Hyperglycemia, hyperosmolar  
Non ketonic coma 
Polydipsia, polyuria, fatigue, blurred vision 
Blindness, retinopathy 
Neuropathy 
Atherosclerosis 
Peripheral vascular disorder, limb 
amputation, infection 
Cerebrovascular disease 
Macrovascular complications Microvascular complications  
Stroke 
Heart disease, hypertension  
Peripheral vascular disorder  
Foot problems  
Retinopathy and cataracts 
Renal disease 
Neuropathy  
Foot problems 
 
 
1.3.4 Prevalence and incidence of DM  
 
NCDs such as Diabetes mellitus have caused global concern, because over 422 million people 
are affected worldwide with millions more projected to become affected by the disease in the 
coming years. For instance, the International Diabetes Federation (IDF, 2011), reported that 
approximately 552 million people will be affected by the year 2030 and it will become the 7th 
leading cause of mortality. This incidence trend was observed to be higher in the low and mid- 
income countries as compared to high income countries (WHO, 2016). Diabetes affects 
individuals who are predominantly between the ages of 40-59 years (IDF, 2011). According to 
 
10 
 
MANAF et al., (2016), about 11% of the pre-diabetic population are diagnosed with Type 2 
diabetes annually. 
Diabetes was once unheard of in the African continent, however, at present Africa is also faced 
with the diabetes crisis and the prevalence has abruptly increased over the years 
(CHINSEMBU, 2018). In the Sub-Saharan Africa (SSA) region, about 10.8 million people 
were inflicted with diabetes in 2006 but the figure is projected to increase to 18.7 million by 
the year 2025, exceeding the global rise of 55% (LEVITT, 2008). The burden of diabetes is 
set to become higher in third world countries than first world countries. In South Africa (SA), 
DM is the second leading cause of death with increased statistics of a 5.4% mortality rate with 
over two million people diagnosed as diabetic (ERASTO et al., 2005; STATS SA, 2017). 
Higher prevalence’s have been observed in the Indian and Black communities (JOUBERT et 
al., 2007; SEMENYA et al., 2012). Provinces such as Limpopo and KwaZulu-Natal have the 
highest burden of DM in SA (JOUBERT et al., 2007; SEMENYA et al., 2012). 
1.3.5 Control and management of DM 
 
Individuals with DM should have easy access to advanced care provided by well-trained health 
care providers. Although diabetes is a chronic disease, health facilities should be established to 
accommodate patients of DM and should be organised in order to provide interventions such 
as physical activity or blood glucose control treatments and allow for frequent check-ups 
(WHO, 2016). For better management of diabetes, individuals require early diagnosis as 
prolonged and untreated DM can cause severe health complications (WHO, 2016). 
 Symptoms are more pronounced in T1DM so patients are able to immediately get medical 
check-ups. These symptoms may include thirst, frequent urination and unexplained weight 
loss. However, due to the gradual progression of T2DM, symptoms may not be as pronounced 
until an individual start experiencing some associated complications such as blurred vision, 
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stroke or limb gangrene. GDM requires intense medical supervision during pregnancy. 
Changes in diet and often in extreme cases insulin is used to control GDM (NDC, 2011; WHO, 
2016). 
Patient awareness about the importance of diabetes management contributes greatly in 
controlling diabetes. This along with changes in life style and diet can prevent the development 
of diabetes associated complications. Therefore, it is imperative that patients participate by 
taking treatments to keep their HbA1c level at 6.5% with a combination of other 
recommendations i.e. (exercising and eating healthy) (GOBOZA et al., 2016; NASRI et al., 
2015). For example, as sugar-sweet beverages (SSB) may contribute to obesity and weight gain 
especially in T2DM, SA has come up with a model study that projects that a 20% tax on SSB 
could help reduce obesity in adults thereby reducing the chances of T2DM in adults 
(MANYEMA et al., 2014; HU and MALIK, 2010). Moreover, infections, smoking and 
environmental stress are some of the factors that aggravate diabetes, so families of diabetic 
patients are encouraged to provide support to avoid these factors on a daily basis (GOBOZA 
et al., 2016; NASRI et al., 2015). 
1.3.6 Current drugs used to treat diabetes 
 
A number of drugs (Table 1.2 and Figure 1.4), are used in the treatment and control of diabetes 
and these are categorised as sulfonylureas, metformin, thiazolidinediones, α-glucosidase 
inhibitors and insulin (EZURUIKE and PRIETO, 2014; STRANKS and MEYER, 2016). 
1.3.6.1 Sulfonylureas 
 
Sulfonylureas are a group of potent synthetic, oral anti-hyperglycemic agents available for the 
treatment of T2DM (KATZUNG, 1995). These hypoglycemic drugs promote the production 
of insulin from the pancreatic β-cells by stimulating insulin sensitivity and decreasing the 
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secretion of hepatic glucose (GABOZA et al., 2016; NASRI et al, 2015; KATZUNG, 1995). 
Sulfonylurea drugs have different modes of action and these include increased insulin release, 
decrease in serum glucagon levels and increased target cell sensitivity to insulin (CLARK et 
al., 1997). Sulfonylurea drugs target the adenosine triphosphate potassium (ATP) sensitive 
channels and bind to the sulfonylurea receptors on the pancreatic β-cell plasma membrane. The 
targeted channel then becomes restricted and successively causes changes within the cells of 
the membrane triggering insulin secretion (MODAK et al., 2007). Sulfonylurea drugs have, 
however, been associated with the onset of cardiovascular diseases (NATHAN, 2014). 
1.3.6.2 Metformin 
 
Metformin (Met) belongs to the Biguanide family and is derived from the plant Galega 
officinalis. Met is a hypoglycemic drug which is currently used in the treatment of T1DM 
(KLIP and LEITER, 1990; GOBOZA et al., 2016). Hepatic glucose production is controlled 
by Met by reducing the rate of the hepatic gluconeogenesis (KRENTZ and BAILEY, 2005). 
As the first line of treatment, the drug can also be used to treat pre-diabetic patients and does 
not instigate weight gain but can cause side effects such as diarrhoea, abdominal pain and 
nausea (MATTHAEI et al., 2000; NASRI et al., 2015).  
1.3.6.3 Thiazolidinediones 
 
Thiazolidinediones (TZDs) are a class of oral antidiabetic drugs which have unique functions 
(BASTAKI, 2005). TZDs are also referred to as glitazones, and their main function is to 
improve peripheral sensitivity of insulin in muscles, liver and fat tissues by stimulating the 
peroxisome proliferator-activated receptor gamma (γ) modulators (NATHAN, 2014). Some of 
the side effects caused by these agents include extended hypoglycemia oedema and weight gain 
(PHILIS-TSIMIKAS, 2013; BASTAKI, 2005).   
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1.3.6.4 α-Glucosidase inhibitors 
 
α-Glucosidase inhibitors slow down the absorption of complex carbohydrates from the 
digestive tract and decrease postprandial hyperglycemia, therefore resulting in the production 
of a low glycaemic index (GOBOZA et al., 2016). These drugs can be administered either as 
a monotherapy or in combination with other drugs, whether in T1DM or T2DM treatment, 
because they effectively reduce postprandial hyperglycemia. However, hypoglycaemia may be 
caused when used in combination with insulin or sulfonylurea agents (BASTAKI, 2005; 
KRENTZ and BAILEY, 2005; GOBOZA et al., 2016). The side effects include production 
of excessive gas and abdominal pain (BASTAKI, 2005; GOBOZA et al., 2016).  
1.3.6.5 Insulin 
 
Insulin (Figure 1.3), is a hormone produced by the pancreatic β-cells (MEHANNA, 2005). 
The entry of glucose into the muscles, liver and fat is enabled by insulin, through the 
stimulation of numerous enzyme reactions from the insulin receptor (ORCI, 1986). Insulin is 
a strong glucose reducing agent with only hypoglycemia as a dose-limiting factor, compared 
to the other oral hypoglycemic agents. However, some patients develop poor glycemic 
control (BASTAKI, 2005). 
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Patients, especially those with T2DM, may develop insulin resistance due to obesity, however, 
insulin resistance is seen as a sign of undesirable changes of the metabolism i.e. (CVDs, blood 
pressure and hyperlipidaemia). Furthermore, the development of insulin resistance in T1DM 
patients has been associated with immunological or non-immunological factors. Reduced 
insulin receptors of target cells result in resistance to the hormone. Common side effects of 
insulin include weight gain and hypoglycemia (BASTAKI, 2005; MEHANNA, 2005).  
There are several insulin treatment preparations as presented in Table 1.2; these are known as 
‘short-acting’ preparations in which insulin absorption is slower and also takes time to reach 
normal prandial effects. Intermediate-acting preparations dissolve gradually and act over a 
longer period. Long-acting preparations are not consistent and are required between meals in 
very low concentrations (KARASU et al., 1995). 
 Due to the severe side effects of the above-mentioned diabetic drugs, most patients seek 
alternative therapy and therefore prefer the use of medicinal plants for treatment. 
Figure 1. 3: Blood glucose regulation by insulin to halt or prevent hypoglycemia or hyperglycemia. 
Image retrieved from: https://www.futurelearn.com/courses/understanding-insulin/0/steps/22457 
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Table 1. 2: Insulin analogs grouped according to duration of action (BASTAKI, 2005).  
Short-acting insulin  
(2-5 h) 
Intermediate-acting insulin  
(18-24 h) 
Long-acting insulin 
(18-36 h) 
Lispro (Humalog)  
Aspart (Novolog)  
Glulisine (Apidra) 
Hexamer 
Dry powder; Liquid suspension 
Neutral Protomaine Hadegon 
[NPH] (Isophane) 
Lente 
Ultralente 
Protoamine zinc 
Glargine 
 
 
 
Figure 1. 4: Oral hypoglycemic drugs used to treat T2DM 
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1.4 The use of medicinal plants to treat ailments  
 
Plants have always been used, not only for shelter and as a food supply but also as medicines 
to treat, prevent and cure a wide range of ailments (SOFORWA, 1984; YAKUBU et al., 
2014). Globally, millions of people depend on medicinal plants for health care (CORDELL, 
1995). Despite the multitude of antidiabetic drugs available on the market, many patients still 
rely on traditional medicine for their primary health care, especially in developing countries 
(WHO, 2016).   
In South Africa, traditional medicines have been a mainstay for centuries and form an essential 
part of various cultures (VAN STADEN, 2008; MANDER, 1998). Approximately 3,000 
indigenous medicinal plant species have been identified as they are habitually used, however, 
only a few have been validated and commercialised (VAN WYK, 2008). The use of traditional 
medicine is still a common practice in SA and approximately 27 million people are dependent 
on it. The majority of South African black communities reportedly consult healers and use 
traditional medicine as their primary source of health care (VAN WYK, 2008). For example, 
in KwaZulu-Natal 83% of the population is dependent on traditional medicine. Traditional 
healers and herbalists use various medicinal plants to heal, treat or cure numerous ailments 
(MANDER, 1998; STATS SA, 2017). 
South Africa has experienced a gradual increase in the number of traditional healers with an 
estimated 200, 000 actively practicing healers (MANDER, 1998). Furthermore, the practicing 
traditional healers use various plant materials as a source of indigenous medicinal remedies 
(MANDER, 1998; VAN VUUREN and VILJOEN, 2011). The use of these indigenous 
medicines stems from different cultural and religious beliefs and is not only limited to the rural 
communities, they are also used for healing purposes in certain parts of urban communities 
(DOLD and COCKS, 2002; MANDER et al., 2007; MAKUNGA et al., 2008; NDHLALA 
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et al., 2011). The wide use of traditional medicine is due to the fact that they are cost effective, 
readily available and easily accessible and are believed to cause minimal side effects (WHO, 
2008).  
The demand for traditional medicine is very high owing to the ever increasing human 
population and prevalent ailments such as diabetes (MANDER, 1998). For instance, Zulu 
traditional healers and herbalists utilise plant material in enormous quantities to satisfy the 
needs of their patients, and as a result, the KwaZulu-Natal ‘muti’ markets reportedly trade 
about 400 plant species amounting to an estimated 4,300 tonnes of plant material per year 
(MANDER, 1998; CUNNINGHAM, 1988). The demand is further propelled by the high cost 
of oral antidiabetic synthetic drugs, insulin and the detrimental side effects of the treatments 
(BALAJI et al., 2015). 
 
1.5 Drug discovery from medicinal plants 
 
A drug according to RATES (2001) can be defined as “a pharmacologically active compound, 
which is a component of a medicine, irrespective of its natural, biotechnological or synthetic 
origin”. Various drugs are used to prevent, treat, heal or even cure diseases. Many drugs are 
derived from natural sources such as plants, minerals and animals (RATES, 2001). Compounds 
from medicinal plants are major scaffolds for the development of modern synthetic medicine 
and contribute largely to the pharmaceutical industries, accounting for approximately 50% of 
derived drugs (PAN et al., 2013). Ethnopharmacology still continues the drive for the 
discovery of new and potent plant derived medicinal compounds (FABRICANT and 
FARNSWORTH, 2001).   
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The discovery of isolated medicinal compounds from plants began in 1805 with the German 
pharmacist Friedrich Serürner who isolated morphine from the plant Papaver somnifererum 
(KINGHORN, 2001). Isolated bioactive compounds could either be used as direct novel drugs 
or may serve as scaffolds for succeeding generations of drugs (FABRICANT and 
FARNSWORTH, 2001).  
Although it is of importance to devise improved natural medicines, there are numerous 
challenges that are encountered during the process of drug discovery which include high costs 
(about 800 million dollars), lengthy time periods (approximately 10 years) and insufficient 
yield of the natural compounds for further optimization and clinical trials (DICKSON and 
GAGNON, 2004; BALUNAS and KINGHORN, 2005). Therefore, in order to become 
successful, scientists need to develop enhanced and rapid procedures to allow the drug 
development phase to keep up to speed with other drug discovery ventures (BUTTLER, 2004).  
 
1.6 Rationale/Problem Statement 
 
The current drugs administered for the treatment of DM do not cure but alleviate the symptoms 
(PELTZER et al., 2001). Thus, due to the complications and side effects associated with DM 
and treatment regimes, in addition to factors such as limited resources and accessibility to 
health facilities, medicinal plants have become an immediate source of relief and are used 
mainly because of their varied biological activities, availability, cost effectiveness and minimal 
side effects (GURUB-FAKIM, 2006; EKOR, 2013; ANDRADE-CETTO and 
WIEDENFELD, 2004). For example, KwaZulu-Natal province has the highest unemployment 
rate resulting in increased poverty and consequently people do not have easy access to clinics 
or hospitals. The agonising waiting lines further aggravate the problem and this in turn impacts 
negatively on the management and control of DM because people shun visiting hospitals and 
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clinics (SEMENYA et al., 2012; PILLAY et al., 2016). Medicinal plants are the nearest 
source of relief with minimal side effects. A number of these plants have shown the potential 
to act as blood glucose level reductants or may act as inhibitors of glucose absorption from the 
gastrointestinal tract thus slowing down postprandial hyperglycemia (GURUB-FAKIM, 
2006). It has been reported in ethnobotanical literature that approximately 800 plant species 
have anti-diabetic properties, though a limited number of herbs displayed antidiabetic activity 
when tested using current methods including screening of α-glucosidase and α-amylase enzyme 
inhibition (OLARCON-AGUILERA, 2000; GURUB-FAKIM, 2006). Antidiabetic activities 
in plants have been associated with the production of chemical compounds including alkaloids, 
glycosides, polysaccharide, peptidoglycans, steroids, carbohydrates, amino acids and inorganic 
ions (GURUB-FAKIM, 2006).  
A large number of plants are yet to be scientifically studied and lack proper documentation 
(MANDER, 1998). Hence there is a need to search for locally important and traditional 
medicinal plants used to treat diabetes. Therefore, this research aspires to identify plants which 
may be used successfully to treat diabetes through scientific investigation and the elucidation 
of active compounds to provide preliminary biological activities of antidiabetic plants and to 
contribute to the growing ethnopharmacology database in SA. 
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1.7 Plants studied 
 
1.7.1 Morphological description and distribution of selected medicinal plants. 
Bulbine natalensis also known as Bulbine latifolia (Asphodelaceae), is commonly known as 
broad-leaved bulbine in English, ibhucu in IsiZulu, rooiwortel in Afrikaans and ingcelwane in 
IsiXhosa. The plant is widely distributed in the eastern and northern parts of South Africa 
(VAN WYK et al., 1997). Bulbine natalensis is a fast growing succulent plant with a 
resemblance of the aloe plant and forms solitary rosettes of up to 20 cm high. It has triangular 
lanceolate evergreen leaves and a floral inflorescence that contain 1-4 densely arranged flower 
racemes with yellow petals (Figure 1.5). The plant has a small rounded capsule fruit and fleshy, 
yellow roots (VAN WYK et al., 1997). 
 
Figure 1. 5:  Bulbine natalensis Baker 
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Kigelia africana (Bignoniaceae) is commonly referred to as cucumber or sausage tree in 
English, worsboom in Afrikaans and umVungata or umFogothi in IsiZulu. The tree grows up 
to 20 m tall or more with a grey and smooth bark as thick as 6 mm (ROODT, 1992; VAN 
WYK et al., 1997).  This tree is distributed from KwaZulu-Natal to Tanzania and can be found 
along open woodland, floodplains and streams (JOFFE, 2003). The tree can be both evergreen 
and deciduous depending on environmental seasons. The leaves are opposite or in whorls of 
three with pinnate oval leaflets, however, the terminal leaflet may be present or absent. The 
tree produces reddish bell shaped bisexual flowers with horizontal orientation growth. The fruit 
is a long woody berry, which hangs from the tree branches and can weigh up to 10 kg (Figure 
1.6). (JOFFE, 2003; VAN WYK et al., 1997).  
 
 
Figure 1. 6:  Kigelia africana (Lam.) Benth. Syn. Kigelia pinnata (Jacq.). Image retrieved 
from: https://en.wikipedia.org/wiki/Kigelia#/media/File:Kigelia_africana_compose.jpg 
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Leonotis leonurus (Lamiaceae) is commonly known as wild dagga or lion’s ears in English; 
wilde dagga in Afrikaans and umcwili or umnyane in IsiZulu. It is mainly found in the 
grassland areas of Eastern Cape, Western Cape, Limpopo, KwaZulu-Natal and Mpumalanga 
(VAN WYK et al., 2000). A soft-woody shrub grows up to 2 m tall. The shrub is composed 
of branched stems with numerous ball-shaped inflorescences of bright orange flowers. The 
stem of the shrub is velvety and delicate and has leaves that are bright yellow green, narrowly 
lanceolate with toothed margins and have a unique strong aromatic smell when crushed. 
Flowering time is from November to January in southern Africa (Figure 1.7) (OYEDEMI and 
AFOLAYAN, 2011; http://pza.sanbi.org/leonotis-leonurus). 
 
 
Figure 1. 7: Leonotis leonurus (L.) R. Br. 
Image retrieved from: https://www.amazon.com/Diamond-Perennials-Leonotis-Leonurus-
Potted/dp/B01HST0NY8 
Sclerocarya birrea (Anacardiaceae) is commonly known as marula in English, moroela in 
Afrikaans and umgamu in IsiZulu (VAN WYK et al., 1997). The marula tree (Figure 1.8) is a 
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medium sized, single-stemmed, terrestrial, erect, perennial deciduous tree of about 10-15 m in 
height (VAN WYK et al., 1997). The stem bark of the tree is flaky with a grey and pale pattern. 
The leaves are compound with different pairs of ovate leaflets and one terminal leaflet present. 
The flowers are presented as small oblong clusters with red and yellow sepals and petals 
respectively (OJEWOLE, 2003). The fruits are pale yellow and contain a kernel with 2-4 seeds 
(VAN WYK et al., 2000; OJEWOLE, 2003). S. birrea is widely distributed in Africa, from 
the north of Ethiopia to the south of KwaZulu-Natal (SA); west of Gambia across Central 
Africa to the east of Kenya and Sudan (VAN WYK et al., 1997; BELEMTOUGRI et al., 
2007). 
 
 
Figure 1. 8: Sclerocarya birrea (A.Rich.) Hochst. Subsp. caffra (Sond.) Kokwaro. Image 
retrieved from: https://commons.wikimedia.org/wiki/File:Sclerocarya_birrea_habitus.jpg 
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1.8 Research objectives  
 
• To investigate and validate selected medicinal plants used in South Africa to treat 
diabetes using in-vitro antidiabetic assays. 
• To evaluate the antioxidant and phytochemical properties of selected plants. 
• To determine whether the plant material exerts any cytotoxicity activity.  
• Due to some antidiabetic complications, the antimicrobial properties of the plant 
species were also assessed. 
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CHAPTER TWO: ANTIOXIDANT ACTIVITY AND 
PHYTOCHEMISTRY OF SELECTED PLANT SPECIES 
2.1 Introduction   
 
Oxidative stress, an imbalance between the production of antioxidants and reactive oxygen 
species (ROS), in favour of the latter, results in a build-up of free radicals further complicating 
the health of diabetic patients (SHORI, 2015; ASMAT et al., 2016). Numerous studies have 
shown that oxidative stress may be induced by free radicals which are produced in the event of 
an increase in blood glucose levels, which in turn aggravates the progression of diabetes 
mellitus (DM) (JOHANSEN et al., 2005). Furthermore, oxidative stress has been reported to 
be a major contributor to the development of vascular complications, especially in Type 2 DM 
(T2DM) (ASMAT et al., 2016). Free radicals are unstable chemical compounds and are the 
result of an imbalance between the production and destruction of reactive oxygen species 
(ROS) (KIBITI and AFOLAYAN, 2015; OYEDEMI and AFOLAYAN, 2011). The 
presence of unpaired electrons makes ROS highly reactive molecules; these include molecules 
such as superoxide anions, hydroxyl nitric oxide and hydrogen peroxide radicals 
(AMAROWICZ et al., 2004; OYEDEMI and AFOLAYAN, 2011). Reactive oxygen 
species, produced by the body as natural by-products, are considered a threat due to their 
abilities to attack and damage DNA molecules, proteins and lipids (AMAROWICZ et al., 
2004). Cellular oxidative damage such as these could lead to the development of several 
diseases such as DM, asthma, inflammation and cancer (SKARBEZ et al., 2010). 
The human body has a range of defence mechanisms which assist in preventing the formation 
of free radicals thereby alleviating oxidation damage (AMAROWICZ et al., 2004; 
POLJSAK et al., 2013). Defence mechanisms include enzymatic and non-enzymatic 
antioxidants such as ascorbic acid (ASC), catalase (CAT), tocopherol, superoxide dismutase 
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and glutathione reductase. The disturbance of these defence functions, due to pathological 
processes, may lead to cellular damage (POLJSAK et al., 2013; SHRUTHI et al., 2012). 
The management of ROS in preventing oxidative stress is a valuable approach which may aid 
in managing DM and associated complications (JOHANSEN et al., 2005). This may be 
achieved through the use of synthetic antioxidants such as butylated hydroxylanisole (BHA) 
and butylated hydroxyltoluene (BHT) or the use of natural antioxidants of plant origin 
(OYEDEMI and AFOLAYAN, 2011; POLJSAK et al., 2013). The use of natural 
antioxidants has become a popular choice for many people because dietary synthetic 
antioxidant drugs cause undesirable side effects such as heart burn; diarrhoea and may become 
carcinogenic or cause genotoxicity, if administered at high concentrations (POLJSAK et al., 
2013; NDHLALA et al., 2010). Furthermore, due to their synergistic actions, natural 
antioxidants from plant sources may be effective ROS scavengers (NDHLALA et al., 2010). 
Medicinal plants are a vital source of antioxidants. A number of studies have demonstrated that 
a diet rich in vegetables and fruits as well as consumption of medicinal plants with high 
antioxidant content may improve hyperglycemia and slow down the development of 
complications associated with diabetes (NISHIKAWA and ARAKI, 2013; NASRI et al., 
2015). The strong medicinal and antioxidant activities of plants may be attributed to the 
presence of secondary metabolites such as phenolics or even nitrogen containing compounds 
as well as carotenoids (ERDEMOGLU et al., 2006; SAINI et al., 2013). For example, 
phenolic compounds have been reported to demonstrate inhibitory activity against 
carbohydrate related enzymes i.e. (α-amylase and α-glucosidase) and may contribute to the 
treatment of increased blood glucose levels after a meal or the management of DM with 
minimal side effects (McCUE and SHETTY, 2004; RANILLA et al., 2010). Therefore, the 
aim of this study was to investigate the phytochemical compounds and antioxidant activities of 
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the selected plant species, which are used traditionally to combat DM and associated 
complications. 
2.2 Materials and Methods     
 
2.2.1 Plant selection and collection 
 
Four plants with reported antidiabetic activity were selected based on the available indigenous 
ethnopharmacological literature of medicinal plants used by various tribes in South Africa for 
the treatment of diabetes and related symptoms (HUTCHINGS et al., 1996; VAN WYK et 
al., 1997). Material of the plant species were collected between February and April 2018. 
Voucher specimens were deposited at the Herbarium [Natal university (NU)] of the University 
of KwaZulu-Natal, Pietermaritzburg for botanical verification and future reference (Table 2.1).
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Plant species Parts used Place of collection Voucher number Traditional use References 
Bulbine natalensis Baker. Leaves and Roots  UKZN Botanical garden MFRatsoma 01 NU The leaves and roots are used to 
treat eczema, syphilis, vomiting, 
diabetes and diarrhoea 
WATT and 
BREYER-
BRANDWIJK, 
1962; OYEDEMI 
et al., 2009.  
Kigelia africana (Lam.) Benth. Leaves and Fruit UKZN Botanical garden MFRatsoma 02 NU Powdered fruit and leaves are 
used to treat ulcers, syphilis, 
diabetes, rheumatism, acne and 
as a purgative. 
HUTCHINGS et 
al., 1996. 
Leonotis leonurus (L.) R. Br. Leaves  Mkhabathini farm KZN AYoung 2999  The leaf concoctions are used to 
relieve headaches, cough, cold, 
influenza, diabetes, delayed 
menstruation, constipation and 
chest infections  
BRYANT, 1966; 
VAN WYK et al., 
2000; 
HUTCHINGS et 
al., 1996. 
Sclerocarya birrea (A.Rich.) Hochst 
subsp caffra (Sond) Kokwaro. 
Stem bark Ga-Mothapo village MFRatsoma 03 NU Stem bark decoction is used to 
treat diarrhoea, gangerous rectis,  
malaria and diabetes  
ELOFF, 2001; 
BRYANT, 1966; 
HUTCHINGS et 
al., 1996; DIMO et 
al., 2007. 
 Table 2. 1: Plant species investigated in this study   
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2.2.2 Extract preparation  
 
The plants were separated into different parts (leaves, roots, fruit and stem bark).  The different 
plant organs were thoroughly washed under running tap water to remove contaminants and 
dried over a period of five days at 50 ºC, in an oven. The dried plant material was ground into 
fine powders using a grinder (IKA®, USA) and stored in brown paper bags in cool 
temperatures.  
Phenolic compounds were extracted from respective ground plant material as described by 
MAKKAR (2000). The ground plant material (1 g/ 20 mL) were extracted with 50% methanol 
in a cold sonication bath (Branson model 5210, Branson ultrasonic B.V Soest, Netherlands) for 
20 min. The resultant extract was filtered under vacuum through Whatman No.1 filter paper 
and the respective filtrates were used immediately for preliminary screening of phytochemical 
compounds and quantifications of polyphenolic content (i.e. total phenolic content; condensed 
tannins and flavonoid content).  
Extracts used to test for biological activities were extracted in the following manner; different 
solvents exhibiting a range of different polarities were used, namely petroleum ether (PE); 
dichloromethane (DCM); acetone (ACE) and water. The ground plant material was extracted 
with the solvents, at different ratios as per the following; PE (20 g / 200 mL), DCM (10 g/ 100 
mL), ACE (5 g/ 50 mL) and water (5 g/ 50 mL). The mixtures except for water, were placed 
on a rotary shaker (Edmund Bühler, Tübingen, German) for 24 h and the resultant suspension 
was sonicated for 1 h in a cold water sonication bath. The maceration was then filtered using 
Whatman No.1 filter paper and concentrated under vacuum using a Rotary evaporator. The 
concentrates were then dried at room temperature under a stream of cold air and later kept at 
10 ºC, in the dark to prevent degradation of light sensitive compounds. Water extracts were 
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collected in pre-weighted glass jars that were stored at -20 ºC and once they were frozen the 
extracts were lyophilised using a Virtis Bench Top freeze dryer. The different dried extracts 
were resuspended to known concentrations prior to analysis of biological activity. 
2.2.3 Antioxidant activity assays   
 
2.2.3.1 β-Carotene/linoleic acid (BCA) model system   
 
The β-Carotene/linoleic acid oxidation suspension or inhibition was determined according to 
the method described by AMAROWICZ et al. (2004).  Sample extracts and BHT (positive 
control) were dissolved in 50% methanol to a known concentration of 7 mg/mL. In a brown 
Schott bottle, 10 mg of β-Carotene was dissolved in 10 mL chloroform. The excess chloroform 
was evaporated under vacuum, resulting in the formation of a thin film of β-Carotene. 
Immediately Linoleic acid (200 µL) and Tween 20 (2 mL) were then added to the thin film of 
β-Carotene and mixed with aerated distilled water (497.8 mL), yielding a final β-Carotene 
concentration of 20 µg/mL. An orange-coloured emulsion was formed from the saturated 
oxygen by vigorously agitating the mixture. Soon after preparation, 4.8 mL of the emulsion 
was dispensed in a test tube, followed by the addition of either sample plant extracts or BHT 
(200 µL, 7 mg/mL), giving a final concentration of 280 µg/mL in the reaction mixture. The 
absorbance for each reaction was measured immediately (t = 0) at 470 nm [Cary 50 UV-visible 
spectrophotometer (Varian, Australia)] following which, the mixture was incubated in a water 
bath at 50 ºC. The absorbance of each reaction mixture was measured every 30 min over a 
period of 180 min. Tween 20 was used to blank the spectrophotometer. The negative control 
was prepared by replacing sample extract with 50% methanol. The rate of bleaching was 
calculated using the following equation: 
Rate of β-Carotene bleaching = [ln (At=0/At=t)] X 1/t 
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Where At=0   is the absorbance of the emulsion at 0 min; At=t is the absorbance at time t (30, 60, 
90 min). The calculated average rate of β-Carotene bleaching was based on rates at 30, 60 and 
90 min. The obtained calculated average rates were then used to determine the antioxidant 
activity (ANT) of sample extracts and are expressed as percentage inhibition of the rate of β-
Carotene bleaching. The following formula was used: 
%ANT = (R control – R sample/ R control) X100 
Where R control and R sample   represent average β-Carotene bleaching rates of negative control 
and plant extracts, respectively. Oxidation rate ratio (ORR) was calculated, to further express 
antioxidant activity of sample extracts using the formula:  
ORR = R sample / R control 
Antioxidant activity (AA) was calculated as described by BRACA et al. (2003) based on the 
inhibition of coupled oxidation of β-Carotene and linoleic acid against the negative control at 
t = 60 min and t = 120 min, the following formula was applied:  
%AA = [1- (A0- At)/ (A00 –A0t)] X 100 
Where A0 is the initial absorbance of sample extract prior to incubation; At  is the absorbance 
at time t = 60 and 120 min for sample extract; A00 and A0t  represent the absorbance of the 
negative control at the beginning of incubation and at time t = 60 and 120 min, respectively. 
2.2.3.2 DPPH (1-1- diphenyl-1-picryhydrazyl) radical scavenging activity   
 
The DPPH technique is reported as the easiest and most widely used method for screening 
antioxidant abilities in foods and plant products (BOLIGON et al., 2014). The free radical 
scavenging activity of plant extracts on the stable radical (DPPH) was estimated by the method 
established by KARIOTI et al. (2004), with modifications. Independently, the sample extracts 
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or standard antioxidant were suspended in 50% methanol to known concentrations beginning 
with the highest concentration at 50 mg/mL. Independently, 15 µL of each of the samples were 
diluted with 735 µL of 50% methanol and added to 750 µL (50 µM in methanol) of a freshly 
prepared methanolic DPPH solution (0.1 mM; prepared in a brown Schott bottle), to give a 
final volume of 1.5 mL in the test tube. The reaction was performed under dim light and was 
incubated in the dark, at room temperature for a period of 30 min. The discolouration of the 
purple DPPH colour in the reaction mixture was measured at 517 nm using a Cary 50 UV-
visible spectrophotometer (Varian, Australia). Absolute methanol was used as the blank 
solution. Standard antioxidants ascorbic acid (ASC) and butylated hydroxyltoluene (BHT), 
were used as positive controls. A negative control was prepared by replacing the sample extract 
or standard antioxidant with 50% methanol. Background correction of the sample absorbance 
(DPPH absent) was completed by subtracting the absorbance readings of sample extract in 
methanol only, from corresponding readings of those obtained in the presence of DPPH. The 
assay was completed in triplicate. This experiment was repeated thrice. The free radical 
scavenging activity (RSA) was calculated according to the formula: 
%RSA= 100 X (1- AE/AD) 
Where AE is the absorbance of the sample or standard antioxidant and AD is the absorbance of 
the negative control. Radical scavenging activity (%) was plotted against concentration of 
sample extract. The concentration required to decrease the absorbance of DPPH by 50% (IC50) 
was calculated using Graph PadPrism 5.  
2.2.3.3 Ferric cyanide (Fe3+) reducing antioxidant power (FRAP) assay    
 
The FRAP assay is a simple, cost effective and efficient spectrophotometric technique 
(BOLIGON et al., 2014). The ferric reducing power of the sample extracts was measured 
according to the method determined by LIM et al. (2009), with modifications. Sample extracts 
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or standard antioxidant (BHT) were independently dissolved in 50% methanol (50 mg/mL), 
from which 30 µL was added to a 96-well micro-plate in triplicate and serially diluted (two-
fold) downwards on the plate. To each well, 40 µL of potassium phosphate buffer (0.2 M, pH 
7.2) and 40 µL of potassium ferricyanide (1% in phosphate buffer, w/v) were sequentially 
added. The microplate was then covered with foil and incubated at 50 ºC for 20 min. Post 
incubation, 40 µL of trichloroacetic acid (10% in phosphate buffer, w/v), 150 µL of distilled 
water and finally, 30 µL ferric chloride (0.1% in phosphate buffer w/v) were added 
sequentially. The microplate was then incubated at room temperature for 30 min in the dark. 
Absorbance of the reduced Fe3+/ ferricyanide complex to the ferrous (Fe2+) form, was measured 
at 630 nm using a micro-plate reader (Opsys MRTM micro-plate reader, Dynex Technologies 
Inc. Chantailly, VA). The potential ferric reducing power of the sample extracts and BHT were 
expressed graphically by plotting the absorbance against concentration. 
2.2.3.4 Hydrogen peroxidase (H2O2) antioxidant assay      
 
The potential scavenging activity of the different plant extracts towards hydrogen peroxide was 
determined according to RUCH et al. (1989) with modification as per NGONDA (2013). The 
solution of hydrogen peroxide (40 mM) was prepared in potassium phosphate buffer (0.2 M, 
pH 7.4). In test tubes, the plant extracts or standard drug (ASC/ BHT) (50 mg/mL) dissolved 
in 50% methanol, were further diluted with the phosphate buffer (1 mL), to which 0.6 mL of 
the hydrogen peroxide (40 mM) solution was added. The final mixture was incubated for 10 
min in a dark room at room temperature. The concentration of hydrogen peroxide in the 
solution was determined by measuring the absorbance at 560 nm using a Cary 50 UV-visible 
spectrophotometer (Varian, Australia) against a blank solution of the phosphate buffer. The 
negative control contained phosphate buffer instead of the sample extract or standard drug. The 
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hydrogen peroxide scavenging activity (%) of the extracts were compared to a reference drug 
ASC and BHT and was calculated using the following formula: 
%Scavenged (H2O2) = AC – AS/ AC   X 100  
Where AC is the absorbance of the control and AS is the absorbance of the extract or the standard 
drugs. The concentration required to decrease the absorbance of H2O2 by 50% (IC50) was 
calculated using Graph PadPrism 5. 
2.2.4 Phytochemical analysis   
 
Phytochemicals occur naturally in plants (ELEAZU et al., 2012). Plants produce and store a 
wide variety of groups of chemical compounds known as secondary metabolites. The 
occurrence of secondary metabolites in plants varies according to the species, ecology and 
biochemical differentiation (GURIB-FAKIM, 2006; LEWINSOHN and GIJZEN, 2009). 
Plant secondary metabolites have long been employed by humans as stimulants and medicines 
(CROZIER et al., 2006). Numerous secondary metabolites including tannins, alkaloids, 
glycosides, volatile oils and resins have been found to be biologically active, affording various 
medicinal uses (NAMDEO, 2007). Secondary metabolites are grouped into three main classes, 
namely; phenolics, saponins and alkaloids (CROZIER et al., 2006). Plant phytochemicals are 
screened because they are important leads for the discovery and development of novel drugs 
(AZWANIDA, 2015). 
2.2.4.1 Phytochemical screening   
 
The preliminary phytochemical screening of crude extracts was determined by using the 
standard qualitative methods as described by EDEOGA et al. (2005) and VERMA et al. 
(2013). 
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2.2.4.1.1 Test for flavonoids  
 
One millilitre of the methanol filtrate was added into a tube and 5 drops of 1% v/v ammonium 
solution was added. The presence of flavonoids would be marked by a yellow discolouration 
of the respective filtrates.  
2.2.4.1.2 Test for alkaloids   
 
Five millilitres of each filtrate was added into 2 mL of hydrochloric acid. To this mixture 1 mL 
of prepared Dragendorff’s reagent was added. An immediate change in colour (orange or red) 
would indicate the presence of alkaloids.  
2.2.4.1.3 Test for terpenoids   
 
Five millilitres of each methanolic filtrate was added to 2 mL of trichloromethane in a test tube, 
to which, 3 mL of concentrated sulfuric acid was added slowly, forming a separate layer. The 
presence of terpenoids was indicated by a reddish-brown colouration on the interface.  
2.2.4.1.4 Test for tannins and phenolic compounds (Ferric chloride test)   
 
In test tubes, 2 mL of each filtrate was added to 2 mL of water into which, 2-3 drops of 5% 
ferric chloride was added. A green or blue precipitate indicated the presence of tannins or 
phenols, respectively. 
2.2.4.1.5 Test for carbohydrates (Benedict’s test) 
 
Five hundred microliters of each filtrate as well as Benedict’s reagent (www.philipharris.co.uk) 
were added to test tubes which were brought to boil at 100 oC in a water bath for 5 min. The 
presence of carbohydrates was indicated by a bluish to green solution while a brown to black 
colouration would indicate the presence of flavonoids as well.  
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2.2.4.1.6 Test for steroids (Salkowski test)   
 
One millilitre of each filtrate was added into 10 mL chloroform and similar amount of 
concentrated sulfuric acid was carefully added down the side of the test tube. To indicate the 
presence of steroids, the upper layer should turn red and the sulfuric acid layer should display 
a yellow to green colouration. 
2.2.5 Quantification of polyphenolic compounds 
 
2.2.5.1 Total phenolic content    
 
The total phenolic contents of selected crude extracts were determined using the Folin-
Ciocalteu (Folin-C) method as described by MAKKAR (2000), with modifications. The 
reaction mixture contained 50 µL of the respective sample filtrates, 950 µL of distilled water, 
500 µL of 1N Folin-C phenol reagent and 2.5 mL of 2% w/v sodium carbonate. This mixture 
was then incubated at room temperature for 40 min. Gallic acid (0.1 mg/mL) was used as a 
standard. Absorbance of the reaction mixture was measured at 725 nm using a Cary 50 UV-
visible spectrophotometer (Varian, Australia). The same procedure was applied to the standard 
solution of Gallic acid (GA) and a standard curve was obtained. The total phenolic content was 
expressed as mg/mL Gallic acid equivalents (GAE) per mg/g dry weight of the crude extracts 
of selected plants. GAE values were reported as X±SE of the triplicate reactions performed.  
2.2.5.2 Condensed tannins  
 
Quantification of total condensed tannins was done using the method described by MAKKAR 
(2000), with modifications. Three millilitres of butanol-HCL reagent (95:5 v/v) were added to 
500 µL of each crude extract. Subsequently, 0.1 mL ferric reagent (0.2% w/v ferric ammonium 
sulphate in 2N HCL) was added. The reaction mixture was vortexed and incubated in a boiling 
water bath for 1 h. Cyanidin chloride (CC) was used as a standard. The absorbance of the post-
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incubation reaction mixture was measured at 550 nm using a Cary 50 UV-visible 
spectrophotometer (Varian, Australia). Absorbance was measured against a blank mixture that 
contained the sample extract (500 µL), butanol-HCL reagent (3 mL) and ferric reagent (100 
µL) without heating. The assay was performed in triplicate. The concentration of condensed 
tannins was expressed as Cyanidin chloride equivalent mg/mL (CCE) per mg/g dry weight of 
the crude extracts.  
 2.2.5.3 Flavonoid content   
 
The determination of flavonoids was measured using the method described by MAKKAR 
(2000), with modifications. The respective plant filtrates (250 µL) were independently diluted 
with distilled water to a volume of 1 mL in a test tube. To this mixture, 5% w/v sodium nitrate 
(75 µL), 75 µL of 10% w/v aluminium chloride, 1M sodium hydroxide (500 µL) and 0.6 mL 
of distilled water were added. Catechin (C) was used as a reference compound (0.1 mg/mL). 
The reaction mixture was measured immediately at 510 nm using a Cary 50 UV-visible 
spectrophotometer (Varian, Australia). A reaction mixture containing 50% methanol without 
the extract was used as a blank. The same procedure was applied to the standard solution of 
Catechin equivalent (CE) and a standard curve was obtained. The flavonoid content was 
expressed as mg/mL Catechin equivalent (CE) per mg/g dry weight of the crude extracts of 
selected plants. All tests were carried out in triplicate.  CE values were reported as X±SE of 
the triplicate reactions performed. 
2.2.6 Statistical analysis 
 
The obtained enzyme data of the plant extracts were subjected to a One-way analysis of 
variance (ANOVA) using IBM SPSS software version 21 for Windows. Significant differences 
(p = 0.05) of the means were separated using Duncan’s Multiple Range Tests and IC50 values 
were conducted on GraphPad Prism Version 4.00 for Windows (GraphPad, Software Inc.)
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2.4 Results and Discussion   
 
2.4.1 β-Carotene and linoleic acid activity of plant extracts   
 
Plant extracts were measured for their ability to delay or prevent the coupled oxidation of β-
Carotene and linoleic acid and the data is presented in Table 2.2. The antioxidant activity based 
on the average rate of β-Carotene bleaching was high for the acetone and water extracts of roots 
of B. natalensis (86.49 and 70.89%, respectively); water extracts of leaves of K. africana 
(76.49%); water extracts of leaves of L. leonurus (80.16%) and acetone and water extracts of 
stem bark of S. birrea (94.58 and 84.81% , respectively) are comparable to the standard control 
BHT (81.75%). The PE extracts of L. leonurus leaves and S. birrea stem bark did not show any 
ability to reduce the bleaching of β-Carotene. The oxidation rate ratio (ORR), associated with 
the antioxidant capacity (ANT %) of the plant extracts ranged from 0.05 to 0.94.  Antioxidant 
activity (AA) based on the inhibition of the oxidation of β-Carotene was further determined at 
t = 60 and 120 min. The antioxidant activity ranged from 2.71 to 76.76% (t=60 min) and 0.18 
to 55.92 (t=120). However, several extracts including PE extracts of S. birrea stem bark (t=60 
min) and B. natalensis roots; acetone and DCM extracts of K. africana leaves; DCM, ACE and 
water extracts of fruits from K. africana; PE extracts of L. leonurus leaves, showed low activity 
while the leaves of K. africana displayed a weak ability to limit β-Carotene bleaching. 
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Plant species Part used Solvent  % ANT ORR AA60 AA120 
Bulbine natalensis Baker. Leaves  PE 37.68±0.30j 0.62±0.003f 13.08±1.15lm 2.60±0.83j 
  DCM 39.36±0.12ij 0.61±0.001fg 15.52±0.31k 11.04±0.15g 
  ACE 28.87±3.54l 0.71±0.004d 7.61±0.62o 8.77±4.97gh 
  Water 33.65±0.24k 0.66±0.002e 14.32±0.79kl 0.18±0.02k 
 Roots PE 31.75±0.17k 0.68±0.002e 6.48±0.38op NA 
  DCM 52.52±0.09f 0.47±0.001j 24.16±0.29h 23.14±0.248e 
  ACE 86.49±0.18b 0.14±0.002n 70.30±0.53b 44.28±0.779bc 
  Water 70.89±0.12e 0.29±0.001k 59.63±0.38e 43.75±0.25bc 
Kigelia africana (Lam.) Benth. Leaves PE 16.61± 0.13n 0.83± 0.001b 12.74±0.22m 3.29±0.22ij 
  DCM 24.33±0.13m 0.76±0.001c 11.15±0.31n NA 
  ACE 5.92±0.19o 0.94±0.002a 5.54±0.14pq NA 
  Water 76.49±0.05d 0.24±0.000l 62.39±0.20d 42.15±0.27c 
 Fruit  PE 24.26±0.19m 0.76±0.002c 20.02±0.20i 7.61±0.10ghi 
  DCM 6.39±0.23o 0.94±0.002a 4.25±0.647q NA   
BHT (control)                       81.75±0.83c                 0.18±0.000m      56.63±0.28f      46.71±0.22bc 
Table 2. 2: The ability of plant extracts in delaying β-Carotene bleaching 
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Values indicate mean ± SE of three replicates. PE= petroleum ether, DCM= dichloromethane, ACE= acetone, BH = butylated hydroxyltoluene. % 
ANT = Antioxidant activity calculated according to the rate of β-Carotene bleaching at t = 60- and 120-min. ORR: oxidation rate ratio, the lower 
the value the stronger the activity. AA60, AA120 = % antioxidant activity of the extract or BHT at t = 60- or 120-min. NA: extracts with no 
activity. Different letters in the same column indicate significant differences at the 5% level of significance. 
Plant species Part used Solvent  % ANT ORR AA60 AA120 
  ACE 44.90±0.28h 0.55±0.003h 14.21±0.66kl NA 
  Water 45.50±0.18h 0.55±0.002h 12.07±0.17mn NA 
Leonotis leonurus (L.) R.Br. Leaves PE NA NA 2.71±0.24r NA 
  DCM 48.39±0.10g 0.52±0.001i 42.32±0.27g 5.14±0.28hij 
  ACE 48.17±0.28g 0.52±0.002i 18.02±0.56j 16.00±0.59f 
  Water 80.16±0.10c 0.20±0.000m 56.71±0.30f 32.82±0.29d 
Sclerocarya birrea (A.Rich) Hoschst. Stem bark PE NA NA NA NA 
  DCM 40.92±0.12i 0.59±0.001g 15.22±0.26k 7.72±0.35ghi 
  ACE 94.58±0.16a 0.05±0.002o 68.55±0.56c 55.92±2.13a 
  Water 84.81±0.23b 0.15±0.002n 76.76±0.22a 47.15±2.15b 
BHT    81.75±0.83c 0.18±0.000m 56.63±0.28f 46.71±0.22bc 
Table 2. 2: Continued 
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2.4.2 DPPH activity of plant extracts   
 
The results pertaining to the antioxidant activity of plant extracts as determined by the DPPH 
radical scavenging assay are illustrated in Table 2.3. The activity varied amongst the different 
plant organs and the solvent used to extract them. Potent radical scavenging activity was 
observed for water and ACE leaf and root extracts of B. natalensis (89.94 and 90.31%, 
respectively), DCM and water leaf extracts of K. africana (94.82 and 97.05%, respectively), 
ACE and water extracts of the fruit (98.04 and 100.00%, respectively) of K. africana DCM, 
ACE and water extracts of leaves of L. leonurus (80.74; 89.48 and 92.98%, respectively) and 
ACE and water extracts of S. birrea stem bark (99.09 and 96.83%, respectively) comparable 
to the standards. Furthermore, the IC50 values of the extracts ranged from 0.01 to 0.22 mg/mL 
(Table 2.3), with water extracts of B. natalensis leaves, DCM and water extracts of the leaves 
of K. africana, water extracts of the fruit of K. africana and the ACE and water extracts of S. 
birrea stem bark exhibited moderate inhibitory concentrations, while ACE extract of fruit of 
K. africana and water extracts of leaves of L. leonurus possessed lower IC50 values that are not 
significantly different  compared to the standards, ASC and BHT (0.02 and 0.02 mg/mL, 
respectively). Extremely low antioxidant activity represented by percentage antioxidant 
activity below 50% at the highest concentration tested, were recorded as not active (NA). 
2.4.3 H2O2 activity of plant extracts 
 
The ability of the plant extracts to reduce H2O2 is represented in Table 2.3. Activities ranging 
from strong to weak were observed for the plant extracts. The ACE extract of roots of B. 
natalensis (35.18%), water extracted fruit from K. africana (21.12%) and ACE and water 
extracts of S. birrea stem bark (22.64 and 30.38%, respectively) demonstrated a strong ability 
to quench H2O2. Water extracts of all the plants displayed moderate to strong activity. However, 
except for the above mentioned extracts, organic extracts of the plants showed very weak 
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activity as compared to that of the standard drugs. The IC50 values ranged from 0.33 to 0.01 
mg/mL. 
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                               DPPH                            H2O2 
Plant species Plant part solvent % RSA IC50 % H2O2 IC50 
Bulbine natalensis Leaves  PE 13.02±0.83jkl NA 99.61±0.023a NA 
  DCM 29.82±3.69h NA 97.20±0.27bc NA 
  ACE 37.03±2.95g NA 94.78±0.08d NA 
  Water 89.94±0.24bc 0.07±0.004bcde 42.18±0.49l 0.33±0.000b 
 Roots PE 10.35±1.02kl NA 98.93±0.00ab NA 
  DCM 20.84±1.67i NA 90.10±0.12d NA 
  ACE 90.31±0.18bc 0.12±0.007abcde 35.87±0.09m 0.26±0.026b 
  Water 57.76±1.69f 0.11±0.013abcde 60.57±0.20j 0.32±0.003b 
Kigelia africana Leaves  PE 52.67±2.76f 0.22±0.150a 64.56±0.13i 0.31±0.001b 
  DCM 94.82±1.28abc 0.05±0.004bcde 74.49±0.37h NA 
  ACE 18.48±0.62ij NA 79.45±0.03g NA 
  Water 97.05±1.00ab 0.03±0.003cde 50.51±0.24k 0.32±0.003b 
 Fruit  PE 8.22±0.34l NA 89.14±0.12e NA 
  DCM 65.93±6.27e 0.14±0.022abcd 94.29±0.03d NA 
  ACE 98.04±0.49a 0.01±0.001de 75.77±0.10h 0.01±0.004d 
  Water 100.00±0.00a 0.08±0.002bcde 21.12±0.60o 0.33±0.000b 
Table 2. 3: Radical scavenging activity (%) of DPPH and H2O2 and their respective IC50 values (mg/mL) 
ASC           92.88±0.45 abc        0.02±0.003de         43.00±2.24l            0.39±0.000a 
BHT           100.00±0.00a        0.02±0.003de         62.81±0.73i            0.27±0.037c 
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                                                                                                                                                              DPPH                                H2O2 
Plant species Plant part solvent % RSA IC50 % H2O2 IC50 
Leonotis leonurus Leaves PE 17.13±1.09ijk NA 97.69±0.011abc NA 
  DCM 80.74±1.27d 0.17±0.006ab 95.65±0.014cd NA 
  ACE 89.48±3.09c 0.16±0.006abc 99.15±0.00abc NA 
  Water 92.98±2.93abc 0.01±0.003de 50.55±0.15k 0.32±0.000b 
Sclerocarya birrea Stem bark  PE 41.99±3.83g NA 94.72±2.31d NA 
  DCM 43.39±4.26g NA 87.31±1.24ef NA 
  ACE 99.09±0.22a 0.03±0.005de 22.64±0.07o 0.13±0.016d 
  Water 96.83±0.54abc 0.02±0.001de 30.38±0.04n 0.31±0.000b 
ASC   92.88±0.45 abc 0.02±0.003de 43.00±2.24l 0.39±0.000a 
BHT   100.00±0.00a 0.02±0.003de 62.81±0.73i 0.27±0.037c 
Table 2.3: Continued 
PE=petroleum ether, DCM= dichloromethane, ACE= acetone, ASC= ascorbic acid, BHT= butylated hydroxyltoluene. Values indicate mean ± SE 
of three replicates. Different letters associated with % RSA and %H2O2 indicate significant differences at the 5% level of significance. IC50= 
sufficient concentration to obtain 50% of a maximum scavenging capacity; NA= Not active 
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2.4.4 FRAP activity of plant extracts   
 
Antioxidant activity of the plant extracts based on their ability to reduce ferricyanide (Fe3+) 
complexes in a solution to its ferrous form (Fe2+) is presented in Figure 2.1. Strong antioxidants 
reduce the Fe3+ complex resulting in a Perl’s Prussian blue colour change that was detected 
spectrophotometrically at 630 nm (NDHLALA et al., 2014). Antioxidant activity varied 
significantly between extracts at the concentrations at which they were tested. Plant extracts 
exhibiting the highest reducing power included PE extracts of fruit of K. africana; DCM 
extracts of leaves of L. leonurus and ACE and water extracts of S. birrea stem bark. Plant 
extracts displaying the weakest reducing power at the highest concentrations tested (12.5 
mg/mL) were PE and DCM extracts of S. birrea stem bark; ACE leaf extracts of K. africana 
and water extract of leaves of B. natalensis. 
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C 
B A 
D 
Figure 2. 1: The dose-dependent ferric reducing antioxidant power of plant extracts. BHT= butylated hydroxyltoluene. Solvents of the extracts 
represented above A= petroleum ether; B= dichloromethane; C= acetone, D= water. Values indicate mean ± SE of three replicates. Different 
letters between samples indicate significant differences at the 5% level of significance. 
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2.4.5 Total phenolic content of plant extracts   
 
This method employed the use of Folin-C reagent and was established on the grounds of the 
oxidation reduction principle. This technique for determining total phenolic content in plants 
was used because it is reproducible and highly sensitive (MAKKAR et al., 2007). The total 
phenolic contents (mg GAE/g DW) of the different plant extracts are presented in Figure 2.2. 
All the plant extracts exhibited different quantities of phenolic compounds, the highest of 
which was observed in stem bark of S. birrea (41,21 mg GAE/g DW), while roots of B. 
natalensis, showed the lowest total phenolic content (5,31 mg GAE/g DW).  
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Figure 2. 2: Total phenolic content of selected medicinal plants. Values indicate mean ± 
SE of three replicates. Different letters between samples indicate significant differences 
at the 5% level of significance.  
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2.4.6 Condensed tannins of plant extracts    
 
The results obtained during the determination of quantities of condensed tannins using the 
butanol-HCL assay are depicted in Figure 2.3. Stem bark of S. birrea displayed the highest 
condensed tannin content (1.91 mg CCE/g DW), while leaves of K. africana exhibited the 
lowest (0.14 mg CCE/g DW). 
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Figure 2. 3: Condensed tannins of selected medicinal plants. Values indicate mean ± SE of 
three replicates. Different letters between samples indicate significant differences at the 5% 
level of significance. 
2.4.7 Flavonoid content of plant extracts 
  
The flavonoid content of plant extracts is presented in Figure 2.4. The tested plant extracts 
exhibited varying quantities of flavonoids. S. birrea stem bark displayed the highest (175,78 
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mg CE/g DW) flavonoid content, whereas leaves of K. africana (30,08 mg CE/g DW) exhibited 
the lowest flavonoid content. 
Figure 2. 4: Flavonoid content of selected medicinal plants. Values indicate mean ± SE of 
three replicates. Different letters between samples indicate significant differences at the 5% 
level of significance. 
 
 
2.4.8 Preliminary phytochemical analysis of the investigated plant extracts   
 
Preliminary assessment of the presence of secondary metabolites in extracts (50% MeOH) of 
the selected medicinal plants revealed the presence of several groups of compounds. All plant 
extracts were positive for the presence of flavonoids, alkaloids and carbohydrates, however, 
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the absence of certain groups of compounds was observed in leaves of B. natalensis (phenols, 
terpenoids, tannins and steroids); fruit of K. africana (phenols and steroids) and leaves of K. 
africana (steroids). 
Table 2. 4: The presence of secondary metabolites in the plants investigated
 
 
 
 
Medicinal plants are a rich source of biologically active secondary metabolites such as 
flavonoids, tannins and phenolic compounds whose bioactivity surpasses that of synthetic 
agents (RAVIPATI et al., 2012; VERMA et al., 2013). The biological activities of these 
plants are often attributed to their ability to stabilize or neutralise free radicals due to the
Plant species K. africana  B. natalensis  L. leonurus  S. birrea 
Plant part Leaves Fruit Leaves Roots Leaves Stem bark 
Flavonoid  + + + + + + 
 
 
Alkaloid 
  
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
Terpenoids 
  
 
+ 
 
 
+ 
 
 
- 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
Phenols 
  
 
+ 
 
 
- 
 
 
- 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
Tannin 
  
 
+ 
 
 
+ 
 
 
- 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
Carbohydrate 
  
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
+ 
 
 
Steroid 
  
 
- 
 
 
- 
 
 
- 
 
 
+ 
 
 
+ 
 
 
+ 
: - indicates absence 
: + indicates presence 
 
 
51 
 
 
 presence of conjugated ring structures, a carboxylic group as well as the nature of their redox 
properties (MANDADE et al., 2011; BOLIGON et al., 2014). The mechanisms by which 
these act include the inhibition of the development and scavenging of ROS, offering reducing 
and metal chelating abilities, inhibiting oxidative enzymes and acting as anti-oxidative 
enzymes (BOLIGON et al., 2014). 
 
The in vitro antioxidant assays revealed that the plant species possess free radical scavenging 
potential dependent on the type of free radical species present. Heat induced oxidation of β-
Carotene and linoleic acid was used to evaluate the ability of plant extracts to delay the 
bleaching of β-Carotene. The orange β-Carotene emulsion undergoes a swift loss of colour due 
to a lack of antioxidants because of the production of free radicals within the system 
(AMAROWICZ et al., 2004; MARIOD et al., 2010). The presence of antioxidants can delay 
the rate of β-Carotene bleaching by stabilizing the linoleate free radical as well as several other 
free radicals that may be formed in the system (AMAROWICZ et al., 2004; MARIOD et al., 
2010). Investigation of plant extracts based on this model revealed a wide range of antioxidant 
activities ranging from very poor to potent. The ACE and water extracts of the stem bark of S. 
birrea demonstrated very high antioxidant activity. Other plant extracts which had notable 
antioxidant activity include, leaves of L. leonurus (water); roots of B. natalensis (ACE and 
water) and leaves of K. africana (water). It was also noted that PE extracts of leaves of L. 
leonurus and stem bark of S. birrea did not display any form of activity against β-Carotene 
bleaching. The leaves and roots of B. natalensis (all extracts, PE and DCM, respectively), 
leaves and fruit of K. africana (organic), leaves of L. leonurus (DCM and ACE) as well as stem 
bark of S. birrea (DCM) displayed very weak antioxidant activity, of which most demonstrated 
an inability to limit the bleaching of β-Carotene after 120 min. Despite the presence of phenolic 
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compounds in these plants, the results contrast with LEONTOWICZ et al. (2003), who 
reported a direct correlation of polyphenolic content and BCA activity in apple peel and pulp. 
However, MARIOD et al. (2010), reported that there is no correlation between the phenolic 
content of plants and their BCA activity, this was also reported by AMAROWICZ et al. 
(2004). Furthermore, the antioxidant activities of plant extracts cannot be anticipated based on 
the total phenolic content because the response of antioxidant activity with phenolic 
compounds on lipid substrates is greatly dependent on chemical structure and oxidation 
conditions (AMAROWICZ et al., 2004). 
 
All plant extracts demonstrated different levels of propensity to reduce DPPH free radicals. 
This action occurs through electrons or hydrogen atom donation, thereby causing a rapid 
decrease in the absorbance of the reaction mixture in the presence of the plant extract 
(AMAROWICZ et al., 2004; BOLIGON et al., 2014). DPPH is a molecule containing a 
stable free radical which is reduced by antioxidant compounds and causes decay of the purple 
chromogen DPPH to a pale-yellow hydrazine (BOLIGON et al., 2014). The DPPH molecule 
can delocalise additional electrons over the entire molecule thus preventing the molecule to 
dimerize as would other free radicals (ALAM et al., 2013). The results obtained in this 
experiment revealed a varied ability of plant extracts (organic and water) to influence DPPH 
radical scavenging. OYEDEMI and AFOLAYAN (2011) reported L. leonurus to be a strong 
DPPH reducer and the results obtained in this study (Table 2.3), displayed by the DCM, ACE 
and water extracts agree with these findings. Moreover, the isolated compound known as 
‘marrubiin’ found in L. leonurus is believed to be associated with its bioactivities (NSUALA 
et al., 2015). Extracts of stem bark of S. birrea (ACE and water) as well as the leaves (DCM 
and water) and fruit (ACE and water) of K. africana, demonstrated strong free radical 
scavenging activity which was comparable to that of the standard control (ASC and BHT). The 
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observed antioxidant activity of S. birrea stem bark in this study concurs with those of 
MASOKO et al. (2008) who reported antioxidant activity of leaves and rhizomes extracts 
(dichloromethane, hexane, and acetone). Furthermore, MOYO et al. (2010) also reported 
radical scavenging activity of young stems of S. birrea and the stem bark of Harpephyllum 
caffrum. The observed activity of the stem bark of S. birrea may be due to the direct 
relationship between the total phenolic content and the antioxidant activity demonstrated 
(AMAROWICZ et al., 2004; MOYO et al., 2010). The ACE leaves and PE fruit extracts of 
K. africana displayed very weak antioxidant activity (18 and 8%, respectively) in accordance 
with AKANNI et al. (2014), who reported weak DPPH activity from fruit of K. africana. 
Contrastingly, DHRITI et al. (2014) reported good antioxidant activity from ACE leaf extracts 
of K. africana (65%), moreover OLUBUNMI et al. (2009), reported that the wax removed 
from the leaves of K. africana displayed very high free radical scavenging activity which is in 
accordance with the results obtained from leaves and fruit extracts of K. africana (DCM and 
water; ACE and water, respectively). These contrasting findings may be attributed to 
geographic variation in phytochemicals and different methods of extraction. The observed 
overall inhibitory potential of the plant extracts against the DPPH radical displayed a range of 
IC50 values (0.01 to 0.22 mg/mL) (Table 2.3), which are directly linked to their antioxidant 
activities indicating their potential as proton donors and possible oxidative stress relievers. 
 
PATEL et al. (2013) reported that hyperglycemia causes augmented productions of hydrogen 
peroxide, which could result in RNA, DNA and lipid impairment. H2O2 is capable of 
infiltrating biological membranes and is thus considered a highly reactive oxygen species 
(CHEN et al., 2012). It is rapidly converted into oxygen and water by a CAT reaction which 
neutralises it, however in the absence of CAT, it may result in the production of hydroxyl 
radicals (OH-) which may induce lipid peroxidation (CHEN et al., 2012; ASMAT et al., 
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2016). It is therefore of importance for antioxidants to remove H2O2 in cells as well as food 
products to prevent cellular damage (KESER et al., 2012). The antioxidant activity (Table 2.3) 
of ACE extracts of roots of B. natalensis; fruit of K. africana; stem bark of S. birrea not only 
displayed strong antioxidant activities but also had higher IC50 values, which where greater 
than those of the reference drugs. The different water extracts of the plants also showed a 
similar trend. These findings concur with KIBITI and AFOLAYAN (2015) who reported that 
the ACE and water extracts of the B. absyssinica showed higher antioxidant activity than the 
standard drugs. Therefore, the obtained results indicate that the bioactive compounds present 
in these plants have the potential to transfer electrons to OH-, produced by H2O2 neutralising it 
to water (LOBO et al., 2010; ASMAT et al., 2016). 
 
The ferric reducing potential of extracts of the different plant species used in this research was 
determined by measuring the reduction of Fe+3 to Fe+2. The results revealed that the plant 
extracts possessed satisfactory reducing abilities which were concentration dependent (Figure 
2.1). The stem bark of S. birrea demonstrated high phenolic content and displayed strong 
reducing power, which was generally higher than that of the standard control (BHT). Several 
researchers have reported the direct relationship between the ferric reducing potentials of plant 
extracts with phenolic content compounds (MOYO et al., 2010). B. natalensis demonstrated 
moderate to weak ferric reducing power but this is contrary to what has been reported by 
SAGBO and MBENG (2018), who reported that the extract of B. latifolia demonstrated strong 
reducing powers, greater than the standard control BHT. The weak antioxidant activity 
demonstrated by B. natalensis concurs with the results of MOSA et al. (2011), who reported 
that B. natalensis is a poor antioxidant agent. The activity of these plant extracts was 
distinguished by the formation of Perl's Prussian blue colouration after ionic reduction of the 
ferric ion/ferricyanide complex to a ferrous form. This conversion is a result of the reaction 
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with ROS, thus converting them to a more stable product and halting the radical chain reaction 
(NDHLALA et al., 2014). The reducing activity of these plant extracts could be linked to their 
ability to donate electrons due to present metabolites (SHARMA et al., 2012).  
 
The results obtained in the present study indicate that the selected medicinal plant species 
contain alkaloids, flavonoids, carbohydrates, terpenoids, tannins and steroids (Table 2.4) as 
well as considerable quantities of total phenolics, condensed tannins and flavonoids (Figure 
2.2; 2.3 and 2.4, respectively). According to BRASILEIRO et al. (2015), numerous 
researchers have demonstrated that phenolic content in plants may vary based on growth stage, 
plant organs as well as environmental conditions. Biologically active compounds such as 
tannins, quinones, saponins, alkaloids, phenolics and terpenoids have previously been 
identified in L. leonurus (OYEDEMI and AFOLAYAN, 2011; LAONIGRO et al., 1979; 
DEMETZOS and DIMAS, 2001). Furthermore, the stem bark of S. birrea demonstrated the 
highest phenolic content. This is in accordance with MOYO et al. (2010) who reported high 
phenolic content in young stem extracts of S. birrea. The phenolic content of the stem bark of 
S. birrea could contribute to the superior antioxidant activity observed in this study. Phenolics 
and flavonoids are the most frequent compounds found in the majority of plants that have been 
reported to possess free radical scavenging potentials (KIBITI and AFOLAYAN, 2015; 
AZWANIDA, 2015). 
 
2.5 Conclusions  
Some of the plants extracts under investigation have demonstrated the presence of secondary 
metabolites and their abilities to act as free radical scavengers. Therefore, these plant species 
may be used to prevent the induction and spread of oxidative chain reactions thereby averting  
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or delaying diseases such as diabetes and diabetic related complications (OYEDEMI and 
AFOLAYAN, 2011).  
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CHAPTER THREE: IN VITRO ANTIDIABETIC AND 
ANTIMICROBIAL ACTIVITIES OF SELECTED MEDICINAL 
PLANTS 
3.1 Introduction   
 
Diabetes mellitus (DM) is a multifaceted chronic disorder distinguished by hyperglycemia 
(RENGASAMY et al., 2013). Hyperglycemia has been reported as a possible cause of the 
non-enzymatic glycosylation of several macromolecules including the mutation of antioxidants 
and/or production of free radical species. Moreover, chronic hyperglycemia may cause damage 
in cells so they are unable to regulate the absorption of sugar (LEBOVITZ, 2001; McCUE 
and SHETTY, 2004; MARTINEZ et al., 2005). A feasible approach to significantly lower 
hyperglycemia, may be through preventing or slowing down the absorption of carbohydrate 
hydrolysing enzymes (i.e. α-amylase and α-glucosidase), postprandialy (ADEMILUYI and 
OBOH, 2013; ORTIZ-ANDRADE et al., 2007). 
The α-amylase carbohydrate enzyme hydrolyses complex polysaccharides by releasing glucose 
through the intestinal α-glucosidase prior to absorption in the gut and circulatory system 
(ADEMILUYI and OBOH, 2013). α-Glucosidase is a vital enzyme responsible for promoting 
intestinal glucose absorption through oligosaccharides and disaccharides cleaving them into 
simple sugars (CHUKWUJEKWU et al., 2016; RENGASAMY et al., 2013). Primarily, α-
amylase inhibitors utilise their hypoglycemic effects by inhibiting salivary and pancreatic 
amylase and are therefore recognised as starch blockers (KAZEEM et al., 2013). Furthermore, 
increased blood glucose levels postprandial may be subdued by α-glucosidase inhibitors which 
could slow down and prolong carbohydrate digestion and digestion time respectively, through 
the inhibition of α-glucosidase in the intestine (KAZEEM et al., 2013). Synthetic agents such 
as voglibose, acarbose and miglitol are broadly utilised as inhibitors of carbohydrate 
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hydrolysing enzymes in Type 2 DM, but they produce undesirable side effects such as 
diarrhoea and flatulence (LEBOVITZ, 1997). 
Infectious diseases are identified as maladies caused by microorganisms such as fungi, bacteria, 
viruses or parasites. These organisms are responsible for the increased human mortality rates 
worldwide. For instance, MORENS et al. (2004) reported that of the 57 million annual deaths 
occurring globally, 25% are associated with infectious diseases.  
Diabetic individuals are vulnerable to infections as a result of their compromised and weakened 
immune systems, caused by chronic hyperglycemia. Moreover, diabetes related complications 
such as nephropathy and atherosclerosis, increase susceptibility to infections in patients 
(ROSS, 2018). In most cases, diabetic patients are more prone to infectious diseases such as 
tuberculosis (TB) and pneumonia (CASQUEIRO et al., 2012). The most prevalent infections 
include foot infections provoked by microorganisms such as Staphylococcus aureus and 
Staphylococcus epidermidis and urinary tract infections (UTIs) mainly caused by uropathogens 
such as Escherichia coli and Enterococcus faecalis. Fournier gangrene affects 70% of diabetic 
males and is triggered by E. coli and Klebsiella sp. (CASQUEIRO et al., 2012). Fungal 
infections such as rhinocerebral mucormycosis, occurs in approximately 50% of DM patients 
and is considered a deadly infection that is promoted by Mucor or Rhizopus. Yeast infections 
such as fungal cystitis, oral and esophageal candidiasis are also frequent, being caused by 
several species of the genus Candida (de LEON et al., 2002; MOHAMMADI et al., 2016; 
CASQUEIRO et al., 2012; ROSS, 2018). These infections may exacerbate diabetic related 
complications such as hypoglycemia and ketoacidosis (PELEG et al., 2007).   
Medicinal plants are reported to possess antidiabetic and antimicrobial properties, owing to the 
presence of a broad range of bioactive compounds (JOSEPH and JINI, 2013). Conventional 
medicines (i.e. acarbose, antibiotics or fungicides) used to treat these ailments are costly, often 
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inaccessible and may cause adverse side effects. Additionally, multi-drug resistance by 
pathogens also make it difficult, not only to clinically manage hyperglycemia but also to treat 
associated infections (MISHRA et al., 2007).  These difficulties have encouraged the use of 
holistic therapies from plants. Therefore, this study was designed to investigate and evaluate 
the antidiabetic and antimicrobial properties of the selected medicinal plants.  
3.2 Materials and Methods   
  
3.2.1 Extract preparation  
 
Extract preparation prior to the execution of the biological experiments were prepared as 
described in Chapter 2, section 2.2.2. The organic (PE, DCM and ACE) and aqueous water 
extracts were dissolved at a concentration of 0.5 dimethyl sulfoxide (DMSO) and 10 (20% 
DMSO) mg/mL for enzyme and antimicrobial assays, respectively.  
3.2.2 In vitro antidiabetic assays  
 
3.2.2.1 α-Amylase inhibition assay   
 
Inhibition of α-amylase assay was performed with the use of the 3.5-dinitrosalicylic acid 
(DNSA) method described by WICKRAMARATNE et al. (2016), with minor modifications. 
Sodium phosphate buffer (0.02 M; SPB) containing 6.7 mM NaCl (pH 6.9), was used to prepare 
α-amylase (from Aspergillus oryzae, Sigma-Aldrich) enzyme solution (2 U/mL). The sample 
extracts were dissolved in 10% DMSO and further dissolved with the SPB to a range of 
concentrations (0.01-0.1 mg/mL). To a test tube, 200 µL each of the extract and the enzyme 
solution were added. The mixture was pre-incubated for 10 min in a water bath at 30 ºC. Post 
pre-incubation, 200 µL of the substrate starch solution (1% in phosphate buffer w/v) was added 
to each tube to start the reaction, which was further incubated for 3 min in a water bath at 30 
oC. The reaction was terminated by addition of 200 µL of DNSA coloring reagent (12 g of 
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sodium potassium tartate tetrahydrate in 8 mL of 2 M sodium hydroxide and 20 mL of 96 mM 
of 3.5-dinitrosalicylic acid solution) and boiled in a water bath at 85 ºC for 10 min. The mixture 
was allowed to cool, and distilled water was added to each test tube to a final volume of 5 mL. 
The absorbance was read at 540 nm using a Cary 50 UV-visible spectrophotometer (Varian, 
Australia). Sodium phosphate buffer was used to blank the spectrophotometer. The negative 
control was prepared by replacing sample extract with 200 µL of buffer (100% enzyme 
activity). Reaction control was prepared identical to that of sample extract for each 
concentration, however, the enzyme solution was replaced by sodium phosphate buffer (200 
µL). Acarbose (0.1 mg/mL) was prepared in the same manner as the sample extract reaction, 
as mentioned above and used as a reference drug.  Percentage inhibition of the enzyme was 
calculated as follows:  
% α-amylase inhibition = 100 x AbsControl − AbsSample / AbsControl 
Abs is the absorbance of either control or sample 
3.2.2.2 α-Glucosidase inhibition assay  
 
The α-glucosidase inhibitory activity of the extracts was determined as described by TAO et 
al. (2013) with modifications as described by RENGASAMY et al. (2013), Potassium 
phosphate buffer (0.1M, pH 6.8; PPB) was used to prepare a α-glucosidase (from 
Saccharomyces cerevisiae, Sigma-Aldrich) enzyme solution (0.1 U/mL) and the 0.375 mM p-
nitrophenyl-a-D-glucopyranoside substrate solution. Sample extracts were dissolved in DMSO 
to known concentrations from (0.1- 0.00625 mg/mL) independently. In a 96-well microtiter 
plate, 20 µL of each sample extract were added into the wells in triplicate and serially diluted 
using a multichannel pipette. To the extract solution, 20 µL of enzyme solution was added and 
the mixture was pre-incubated for 5 min at 37 ºC. To initiate the reaction, the substrate solution 
(40 µL) was added to the reaction mixture and further incubated for 30 min at 37 ºC. Sodium 
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carbonate (0.2 M; 80 µL) prepared in PPB was then added to each well of the mixture to stop 
the reaction. The quantity of p-nitrophenyl produced by the reaction as indicated by the 
intensity of change in colour (yellow) during the reaction was determined using an Opsys MR 
96-well microplate reader at 405 nm. Acarbose dissolved in DMSO (60 mg/mL) and treated in 
the same way was used as reference drug. The phosphate buffer instead of the sample extract 
was used as the control. The percentage inhibition of the enzyme was calculated as follows: 
% α-glucosidase inhibition = 100 x AbsControl − AbsSample / AbsControl 
Abs is the absorbance of either control or sample 
3.2.3 Antimicrobial assays  
 
3.2.3.1 Antibacterial micro-dilution assay   
 
Sample extracts were evaluated for antibacterial activity in the microdilution assay as described 
by ELOFF (1998), where the minimum inhibitory concentrations (MIC) were determined. 
Bacterial cultures including two Gram-positive (Enterococcus faecalis ATCC 19433 and 
Staphylococcus aureus ATCC 12600) and two Gram-negative (Escherichia coli ATCC 11775 
and Klebsiella pneumoniae ATCC 13883) bacterial species were incubated (37 ºC) overnight 
in a water bath with an orbital shaker. The respective bacterial strains were diluted with 20 mL 
sterile Mueller-Hinton (MH) broth (200 µL in 19.8 mL) to a final inoculum concentration of 
106 CFU/mL. Crude organic extracts were suspended in 20% DMSO and water extracts were 
dissolved in sterile water, to a final concentration of 10 mg/mL. In a 96-well microplate, 100 
µL of each sample extracts were serially diluted two-fold with 100 µL of sterile distilled water. 
One hundred microlitres of bacterial strain was then added separately to each of the extract 
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wells. The microplates were covered with parafilm and incubated at 37 ºC for 24 h. A two-fold 
serial dilution of neomycin (Sigma-Aldrich, Steinheim, Germany) (0.1 mg/ml) was used as a 
positive control against each bacterial strain while water was used as the negative control and 
20% DMSO as the solvent control. Subsequently, an indicator, p-iodonitrotetrazolium chloride 
(INT) (Sigma-Aldrich, Germany) (40 µL 0.2 mg/ml) was added to each well to determine MIC 
values after an incubation period of 1 h. The presence of biologically active organisms is 
indicated by the tetrazolium salt which results in a red product. The lack of a colour change 
indicates inhibition of the test organism by the plant extracts. The bioassay was performed with 
three replicates per sample extract or control and repeated twice.   
3.2.3.2 Antifungal micro-dilution assay   
 
The antifungal activity of the extracts was determined using the method described by ELOFF 
(1998). An overnight culture of Candida albicans (ATCC 10231) in a yeast malt (YM) broth 
was incubated in a water bath with an orbital shaker (37 ºC). To 4 ml of sterile saline, 400 µL 
of the fungal culture was added and the absorbance read and adjusted at 530 nm, to match that 
of the 0.5 M McFarland standard solution from which a 1:1000 dilution was prepared with 
sterile YM broth, producing a final inoculum of approximately 106 colony-forming units 
(CFU/mL). The organic sample extracts were suspended in 20% DMSO while the water 
extracts were dissolved in sterile water to a final concentration of 10 mg/mL. In a 96-well 
microplate, 100 µL of each extract were serially diluted two-fold with 100 µL of sterile distilled 
water. One hundred microlitres of the diluted fungal culture was subsequently added to each 
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well. Amphotericin A (Sigma-Aldrich, Germany, 2.5 mg/mL) was used as positive control, and 
a similar two-fold serial dilution was used while water and 20% DMSO served as negative and 
solvent controls, respectively. The microplates were then covered with parafilm and incubated 
at 37 ºC for 24 h.  Post incubation, 40 µL 0.2 mg/ml INT was added from which the plates were 
further incubated for another 24 h at 37 ºC. Clear wells indicated inhibition of fungal activity 
while reddish-pink wells indicated fungal growth. The MIC values of extracts that inhibited 
fungal growth were recorded. The bioassay was performed with three replicate sample extracts 
and repeated twice. 
3.2.4 Statistical analysis 
 
The obtained enzyme data of the plant extracts were subjected to a One-way-analysis of 
variance (ANOVA) using IBM SPSS software version 21 for Windows. Significant differences 
(p = 0.05) of the means were separated using Duncan’s Multiple Range Tests and IC50 values 
were conducted on GraphPad Prism Version 4.00 for Windows (GraphPad, Software Inc.) 
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3.3 Results and Discussion   
 
3.3. 1 α-Amylase inhibitory activity of plant extracts 
 
Plant extracts were measured for their ability to inhibit the α-amylase enzyme responsible for 
starch breakdown in the gut (Figure 3.1). The inhibitory activity of the extracts at 0.1 mg/mL, 
were higher for DCM and water extracts of leaf extracts of B. natalensis (71.13 and 79.45%, 
respectively), water extract of roots of B. natalensis (89.53%),  ACE extract of leaves of L. 
leonurus (73.54%), and water extracts of leaves of K. africana and S. birrea stem bark (75.16 
and 70.65%, respectively) than that of acarbose (64.47%). Moderate inhibitory activity was 
displayed by PE and ACE extracts of leaves of K. africana (41.13 and 47.39%, respectively) 
and ACE roots (33.41%) and PE leaves (36.21%) of B. natalensis, water extracts of L. leonurus 
(32.40%) and DCM and ACE extracts of stem bark of S. birrea (32.40 and 33.81%, 
respectively). The IC50 values presented in Table 3.1, ranged from 0.01 to 0.07 mg/mL, with 
the water extracts of leaves and fruit of K. africana (0.01 and 0.02 mg/mL), PE extracts of 
leaves of K. africana (0.03 mg/mL), water extracts of leaves of B. natalensis (0.03 mg/mL) 
and also water extracts of S. birrea stem bark (0.02 mg/mL) displayed low IC50 values which 
were better and sometimes comparable to that of the standard control (0.03 mg/mL).
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1. K. africana L 
2.   K. africana F 
3.  B. natalensis L 
4.  B. natalensis R 
5.  L. leonurus L 
      6. S. birrea SB 
 
Figure 3. 1: α-amylase inhibitory activity of plant extracts. F= fruit, L= leaves, R= roots, SB= stem bark. Extract 
solvents:  A= petroleum ether, B= dichloromethane, C= acetone, D= water. Values indicate mean ± SE of three replicates. 
SE indicate significant differences at the 5% level of significance. 
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                          IC50 mg/mL 
Plant species Plant part  α-Amylase α-Glucosidase 
Bulbine natalensis Leaves  PE 0.07±0.000a 0.05±0.003a 
  DCM 0.04±0.001efg 0.05±0.012a 
  ACE 0.04±0.003ghi 0.06±0.001a 
  Water 0.03±0.000jk 0.06±0.011a 
 Roots PE 0.04±0.003de 0.05±0.005a 
  DCM 0.06±0.000b 0.04±0.007a 
  ACE 0.05±0.000c 0.05±0.002a 
  Water 0.04±0.001ij 0.06±0.010a 
Kigelia africana Leaves  PE 0.03±0.000l 0.06±0.001a 
  DCM 0.05±0.000c 0.07±0.001a 
  ACE 0.04±0.001ghij 0.05±0.004a 
  Water 0.01±0.000m 0.04±0.013a 
 Fruit  PE 0.05±0.000d 0.05±0.004a 
  DCM 0.04±0.003efg 0.05±0.006a 
  ACE 0.04±0.000hij 0.04±0.002a 
  Water 0.02±0.000n 0.03±0.016a 
Leonotis leonurus Leaves PE 0.06±0.000b 0.04±0.003a 
  DCM 0.05±0.000c 0.03±0.007a 
  ACE 0.04±0.003def 0.04±0.010a 
  Water 0.04±0.002efg 0.05±0.014a 
Sclerocarya birrea Stem bark  PE 0.04±0.000fgh 0.05±0.002a 
  DCM 0.04±0.001fgh 0.05±0.008a 
  ACE 0.06±0.002b 0.02±0.001a 
  Water 0.02±0.000m 0.03±0.008a 
Acarbose   0.03±0.000kl 1.20±0.027b 
Table 3. 1: IC50 values of the α-Amylase and α-Glucosidase activity of extracts 
Values indicate mean ± SE of three replicates. PE= petroleum ether, DCM= 
dichloromethane, ACE= acetone. Different letters in the same column indicate significant 
differences at the 5% level of significance 
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3.3.2 α-Glucosidase inhibitory activity of plant extracts   
 
 
The potential of the plant extracts to inhibit the α-glucosidase enzyme was measured (Figure 
3.2). High inhibitory activity of the extracts at 0.1 mg/mL, was observed from DCM and ACE 
extracts of roots of B. natalensis (98.84 and 96.42%, respectively), ACE extracts of leaves of 
B. natalensis (72.49%), ACE extracts of fruit of K. africana (84.23%) and ACE and water 
extracts of S. birrea stem bark (94.04 and 95.53%). Weak to moderate inhibitory activity was 
observed from all water extracts except for S. birrea (95.53%). All IC50 values of the extracts 
ranged from 0.02 to 0.07 mg/mL which were significantly lower than the standard control 
acarbose (1.20 mg/mL). 
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2. K. africana L 
2.   K. africana F 
3.  B. natalensis L 
4.  B. natalensis R 
5.  L. leonurus L 
      6. S. birrea SB 
Figure 3. 2:  α-glucosidase inhibitory activity of plant extracts. F= fruit, L= leaves, R= roots, SB= stem bark. Extract 
solvents: A= petroleum ether, B= dichloromethane, C= acetone, D= water. Values indicate mean ± SE of three replicates. 
SE indicates significant differences at the 5% level of significance 
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3.3.3 Antibacterial and antifungal activity of plant extracts under investigation 
 
The minimum inhibitory concentration (MIC) values (antibacterial and antifungal) of the plant 
extracts are presented in Table 3.2. Twenty-four plant extracts of the selected plant species 
were screened for antimicrobial activity. The results suggest that some of the investigated plant 
extracts were able to inhibit the pathogenic strains, while others were inconclusive and required 
a concentration above that of the highest tested concentration (Table 3.2). Broad spectrum 
antimicrobial inhibitory activity against both the bacterial and fungal strains was demonstrated 
by the DCM extract of roots of B. natalensis, ACE and water extract of S. birrea stem bark and 
ACE extracts of leaves of L. leonurus. In addition, the DCM extract of leaves of B. natalensis 
and the ACE extract of roots of B. natalensis displayed effective microbial inhibitory activity 
against all bacterial strains used. However, water extracts of leaves and roots of B. natalensis, 
leaves of K. africana and L. leonurus, showed no noteworthy antimicrobial activity.
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   S.a E.f E.c K.p C.a 
     
Plant species Plant part 
 
      
Bulbine natalensis Leaves  PE 0.63 0.63 0.02 2.50 2.50 
  DCM 0.31 0.31 0.02 0.31 1.25 
  ACE 1.25 1.25 2.5 1.25 1.25 
  Water >2.50 2.50 >2.50 >2.50 >2.50 
 Roots PE >2.50 >2.50 >2.50 >2.50 2.50 
  DCM 0.63 0.63 0.63 0.16 0.16 
  ACE 0.16 0.16 0.02 0.16 >2.50 
  Water 1.25 >2.50 >2.50 >2.50 >2.50 
Kigelia africana Leaves  PE 0.31 1.25 0.02 2.50 2.50 
  DCM 0.31 0.31 0.02 >2.50 2.50 
  ACE 0.63 0.63 0.02 2.50 2.50 
  Water >2.50 >2.50 2.50 2.50 >2.5 
 Fruit  PE >2.50 >2.50 >2.50 >2.50 2.50 
  DCM >2.50 >2.50 >2.50 1.25 >2.50 
  ACE 0.63 0.31 0.63 >2.5 >2.50 
  Water 0.63 0.63 >2.5 >2.5 >2.50 
Leonotis leonurus Leaves PE 1.25 2.50 0.63 2.50 0.02 
  DCM 2.50 0.08 0.63 2.50 1.25 
  ACE 0.63 0.31 0.63 0.31 0.02 
  Water >2.50 >2.50 >2.50 >2.50 >2.50 
Sclerocarya birrea Stem bark  PE >2.50 >2.50 >2.50 >2.50 2.50 
  DCM 2.50 >2.50 1.25 2.50 2.50 
  ACE 0.16 0.08 0.02 0.16 0.16 
  Water 0.31 0.31 0.63 0.63 0.04 
        
Neomycin (µg/mL)   0.78 0.63 0.16 0.16  
Amphotericin B 
(µg/mL) 
      
0.93 
Table 3. 2: Antibacterial and antifungal activity (MIC mg/mL) of extracts. 
Values indicate mean of three replicates. PE= petroleum ether, DCM= dichloromethane, ACE= acetone, 
S.a= Staphylococcus aureus, E.f= Enterococcus faecalis, E.c= Escherichia coli, K.p= Klebsiella 
pneumoniae, C.a= Candida albicans. Values in bold are considered very active (MIC ≤ 1 mg/mL). 
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The management of DM is a major global challenge with effective therapies still to be 
discovered (KAZEEM et al., 2013). Early metabolic impairments identified from diabetic 
patients is displayed by increased postprandial hyperglycemia (BLAAK et al., 2012). The 
critical approach in the management of DM involves achieving the control of postprandial 
hyperglycemia which, if left untreated could lead to the development of microvascular and 
macrovascular complications (CHANG et al., 2013; ADEMILUYI and OBOH, 2013). 
Frequently used hypoglycaemic medicines in the treatment of T2DM include α-glucosidase 
inhibitors such as acarbose. Acarbose is a nitrogen-containing pseudo-tetrasacharride, forming 
part of the α-glucosidase inhibitor group (SHIBAO, 2012). However, acarbose has been 
reported to exhibit very little to no inhibitory activity against α-glucosidase hence the upsurge 
of interest in the search for more effective treatments (ANAM et al., 2009; SHAI et al., 2010). 
Medicinal plants and herbal therapies have been marked as efficient approaches to inhibiting 
the major DM associated enzymes (α-amylase and α-glucosidase) to reduce the level of blood 
glucose after a meal (ADEMILUYI and OBOH, 2013; KONATE et al., 2014). As part of 
their defence mechanisms plants produce a wide variety of compounds, some of which are 
glucosidase inhibitors and may be effective in the suppression of hyperglycemia (KAVIMANI 
et al., 2014). 
The in vitro antidiabetic assays demonstrated the inhibitory activity of the selected plant 
species. The inhibition of the pancreatic α-amylase enzyme may reduce the breakdown of 
starch in the small intestine, thereby lowering plasma glucose levels (SARAVANAN and 
PARIMELAZHANGAN, 2014). The results of the present study (Figure 3.1) revealed the 
strong inhibitory activity of leaf extracts of B. natalensis (DCM and water), leaves of L. 
leonurus (ACE), leaves of K. africana (water) and S. birrea stem bark (PE and water). A study 
by KAZEEM et al. (2013), reported high α-amylase inhibitory activity by leaf extracts of 
Morinda lucida. Furthermore, potent α-amylase inhibition by plant extracts have been reported 
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previously to lead to irregular bacterial fermentation of undigested carbohydrates in the gut, 
therefore only moderate α-amylase inhibition is desirable (KAZEEM et al., 2013). Mild 
inhibitory activity was demonstrated by leaves of K. africana (PE and ACE), leaves of B. 
natalensis (PE), roots of B. natalensis (DCM and ACE), leaves of L. leonurus (water) and stem 
bark of S. birrea (DCM and ACE). DHRITI et al. (2014), reported a significant reduction in 
α-amylase activity from the ethanolic leaf extract of K. africana, which concurs with the 
obtained findings. The α-amylase inhibitory activities of the plant extracts may be due to the 
presence of secondary metabolites such as tannins and flavonoids. Phytochemicals such as 
phenolic acids and flavonoids are reported to be covalently attached to the α-amylase and alter 
its activity because of the capacity to develop quinones or lactones which can react with 
nucleophilic groups found on the enzyme (OYEDEMI et al., 2013).   
 
Potent α-glucosidase inhibitory activity (Figure 3.2) was displayed by roots of B. natalensis 
(DCM and ACE, respectively), leaves of B. natalensis (ACE), fruit of K. africana (ACE) and 
S. birrea stem bark (ACE and water). These results conform with those of KWON et al. (2006), 
who reported that natural 𝛼-glucosidase inhibitors from plants have been shown to exhibit 
strong inhibitory activity against 𝛼-glucosidase i.e. (rosemary and sage) and thus could serve 
against postprandial hyperglycemia with minimal side effects. The potent inhibitory activity of 
S. birrea corroborates with those reported by DIMO et al. (2007), who showed that 
dichloromethane: methanol (1:1) extracts could decrease hyperglycemia while increasing 
plasma insulin levels in streptozotocin (STZ) rats. Additionally, a study done by VAN DE 
VENTER et al. (2008), revealed that a methanol extract of S. birrea led to a notable rise of 
glucose use in Chang liver cells. The reported bioactivity of ACE and aqueous extracts of S. 
birrea may be due the presence of phytochemicals such as terpenes and flavonoids, which have 
been reported to exhibit hypoglycaemic activities (PATEL et al., 2012). PRIYA et al. (2014) 
 
73 
 
reported a methanolic leaf extract of K. africana was found to reduce serum glucose levels in 
alloxan-induced diabetic rats. Although the leaf extracts of L. leonurus in this study 
demonstrated moderate to weak inhibitory activity, OYEDEMI et al. (2011) demonstrated the 
hypoglycemic potential of the water extracts of the leaf of L. leonurus as well as it’s 
antilipidemic effects in STZ-induced diabetic rats. Several secondary metabolites were noted 
from the evaluated plant species (Chapter 2). Secondary metabolites generally play vital roles 
in phytomedicines, for instance they are known to stimulate and regulate the liberation of 
insulin in the pancreas for glucose uptake by the muscle tissue (VIRGINIE et al., 2016). 
Alkaloids have also been reported to possess anti-hyperglycemic activities because of their 
ability to inhibit and reduce 𝛼-glucosidase and glucose transport through the intestinal lining 
(PAN et al., 2003). Additionally, flavonoids have also been known to regenerate injured β-
cells in diabetic rats, therefore they are also considered effective hypoglycemic agents 
(CHAKRAVARTHY et al., 1980; MANICKAM et al., 1997).  
 
The PE and DCM extracts of leaves of B. natalensis displayed good (0.63-0.02 mg/mL) 
bioactivity against the Gram-positive (Staphylococcus aureus and Enterococcus faecalis) and 
Gram-negative (Escherichia coli and Klebsiella pnuemoniae) bacteria. No noteworthy activity 
from the ACE and water extracts were demonstrated. In addition, the roots of B. natalensis 
(DCM and ACE) showed potent bioactivity against all the tested bacterial strains, however, PE 
and water extracts displayed reduced antibacterial activity against the pathogens. These 
findings concur with YAKUBU et al. (2012), who reported noteworthy antibacterial activity 
of ethanol B. natalensis tuber extracts against several pathogens including (S. aureus, E. coli 
and K. pneumoniae). The human intestinal flora contains E. coli which could cause diseases in 
incapacitated individuals or those with weakened immune systems, therefore it is of importance 
to note that the bacterium which is known to be multi-drug resistant was sensitive towards the 
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leaf and root extracts of B. natalensis (CVETANOVIC et al., 2019). The water extracts 
generally displayed weak bioactivity RABE and VAN STADEN (1997), have reported that 
most water extracts exhibit very weak if not undetectable antibacterial activity in some plants. 
Petroleum ether is employed to extract fatty acids in plant material, this may be the reason for 
the potent antibacterial activity of the PE leaf extracts of the B. natalensis. A number of 
researchers (RUSSELL, 1991; OUATTARA et al., 1997, WILLE and KYDONIEUS, 2003) 
have demonstrated the antibacterial nature of fatty acids in plant extracts.  
Numerous researchers (CHENIA, 2013; FOMOGNE-FODJO et al., 2014; KONE et al., 
2004; NAIDOO et al., 2013), have demonstrated a range of antibacterial effects of K. africana 
against different bacterial strains, bacteria were sensitive towards the leaf extracts of K. 
africana (DCM), S. aureus, E. faecalis and E. coli (0.31 and 0.02 mg/mL, respectively). No 
noteworthy activity against other bacterial strains (E. faecalis and K. pnuemoniae) were 
recognized. Moreover, the fruit extracts (ACE), exhibited bioactivity against (S. aureus, E. 
faecalis and E. coli), while water extracts only exhibited activity against (S. aureus, E. 
faecalis), however strong bacterial activities were displayed by ACE and DCM extracts. The 
stem bark and fruit of K. africana have been reported to show antibacterial activity (McGAW 
et al., 2000; AKUNYILI et al., 1991) to which the bioactivity may be attributed to the presence 
of iridoids (AKUNYILI et al., 1991). Different plant parts displayed the presence of tannins 
(Chapter 2), these secondary metabolites have also been reported to have antibacterial activity 
(VERMA et al., 2013). These findings concur with HUSSAIN et al. (2016), who reported 
high sensitivity of E. coli toward ethanol leaf extracts of K. africana while K. pneumonia was 
resistant. Additionally, SAINI et al. (2013) reported maximum activity of the aqueous fruit 
extract against S. aureus. However, these results are in contrast with McGAW et al. (2000), 
who reported antibacterial activity of the root and aerial parts of the plant tested against the B. 
subtilis, E. coli, S. aureus and K. pnuemoniae bacterial strains. Furthermore, 
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JEYACHANDRAN and MAHESH (2007), reported moderate antibacterial activity against 
E. coli and S. aureus from methanolic extracts of the plant and no activity from aqueous 
extracts. The difference in the acquired bioactivity of this plant may be due to geographical 
distribution, environmental stress as well as storage of the crude extracts (RATES, 2001; 
STAFFORD et al., 2005). Different K. africana plant parts in this report have displayed strong 
inhibitory activity against the multi-drug resistant K. pnuemoniae, the bacterium responsible 
for causing infections in the skin, surgical wounds and urinary tract infections especially in 
diabetic patients (NDHLALA et al., 2014). 
Leaf extracts of L. leonurus (PE) were active against E. coli (0.63 mg/mL), while DCM 
demonstrated activity towards E. coli and E. faecalis. The acetone extract was active against 
both Gram-positive and Gram-negative bacterial strains, but water extracts only exhibited weak 
antibacterial activity. The leaves of L. leonurus demonstrated the presence of some secondary 
metabolites which have been recognized as bioactive compounds (phenolics and flavonoids), 
exhibiting anti-inflammatory and antimicrobial activities among others (OYEDEMI and 
AFOLAYAN, 2011; HUTCHINGS et al., 1996). However, KELMANSON et al. (2000) 
reported no noteworthy antimicrobial activity of L. leonurus which is contrary to the results 
obtained in the present study. JIMOH et al. (2010), reported that ACE and methanol extracts 
of the leaves of L. leonurus demonstrated antimicrobial activities (MIC 1-5 mg/mL) against a 
number of bacterial strains including S. aureus and E. coli, but that water extracts did not show 
antibacterial activity. K. pnuemoniae a bacterium frequently associated with nosocomial 
infections was susceptible to leaf extracts of L. leonurus, concurring with the obtained findings. 
The results are of significance considering the inhibition of E. faecalis by the leaf extracts as 
this bacterium has been identified as the most commonly isolated species in diabetic foot ulcers 
and is highly resistant to antibiotics such as erythromycin (SHETTIGAR et al., 2018). 
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The PE and DCM extracts of stem bark of S. birrea extracts showed very weak bioactivity 
against the tested bacterial strains but the ACE and water extracts demonstrated strong 
inhibition of all bacterial strains. The results strongly concur with ELOFF (2001) who reported 
growth inhibition of the stem bark against the uropathogens (S. aureus, Pseudomonas 
eruginosa, E. coli and E. faecalis). MOYO et al. (2011) also reported the highest bioactivity 
against the Gram-positive and Gram-negative bacteria (MIC ≤ 0.195 and < 1.0 mg/mL, 
respectively) from ethanolic S. birrea twig extracts. Similarly, McGAW et al. (2000) reported 
high antibacterial activity from mature S. birrea stem bark against Bacillus subtilis (0.0195 
mg/mL) and S. aureus (0.049 mg/mL). The antibacterial activity of the S. birrea water extracts 
are in accordance with a number of studies that have reported good antibacterial activity of 
other plant water extracts i.e. Alepidea natalensis (BUWA and VAN STADEN, 2006; 
MULAUDZI et al., 2009). The antibacterial activity of the S. birrea stem bark may be due to 
the presence of secondary metabolites reported to show antibacterial and anti-inflammatory 
activity (CROZIER et al., 2006). 
Gram-positive bacteria displayed more sensitivity to the plant extracts than the Gram-negative 
bacteria which demonstrated resistance against the extracts, owing to their complex cell wall 
which is comprised of a peptidoglycan-containing matrix and lipopolysaccharides which make 
it difficult for antibacterial agents to permeate through the cells (MOYO et al, 2011). 
Potent antifungal activity was demonstrated by a few plant extracts against C. albicans. The 
extracts of K. africana did not show any fungicidal activity. These results are in accordance 
with HAMZA et al. (2006) who reported that the fruit methanolic extracts of K. africana 
displayed activity only against Cryptococcus neoformans while other strains such as C. 
ablicans and Colletotrichum papaya were resistant. Although fatty acids have been reported to 
be potent antimicrobial agents (WILLE and KYDONIEUS, 2003), the PE and DCM stem 
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bark extracts of S. birrea have shown no fungicidal activity. This is in agreement with 
MASOKO et al. (2008), who reported inactivity of non-polar S. birrea solvent extracts against 
test organisms such as Candida albidus and C. parapsilosis. However, in the same study the 
acetone, ethanol and methanol extracts were found to inhibit the fungal organisms. 
Furthermore, RUNYORO et al. (2006), reported the antifungal activity of the ethanolic 
extracts of the S. birrea stem bark against C. ablicans.  The PE and ACE leaf extracts of L. 
leonurus displayed very strong antifungal activity (MIC 0.02 mg/mL), partly in agreement with 
MAZIMBA (2015), who reported that the ethanolic and ethyl acetate extracts demonstrated 
moderate antifungal activities against of C. albicans, while the hexane and aqueous extracts 
did not show any activity. The DCM roots of B. natalensis also demonstrated very strong 
antifungal activity against the test organism. In line with these findings, GHUMAN et al. 
(2016), reported potent antifungal activity from the chloroform leaf extracts of B. natalensis 
(0.63 mg/mL) against the test organism C. albicans. The different plant parts contain several 
polyphenols such as phenolics, flavonoids and tannins which have been reported to possess 
antifungal activity. This activity however, is partially dependent on the position and number of 
hydroxyl groups in the compounds and thus they may inhibit the microorganism either through 
a reaction with sulphur hydral groups or non-specific contact with proteins (ARIF et al., 2009). 
3.4 Conclusions  
 
The plant extracts in this report have exhibited their abilities to inhibit both the diabetic related 
enzymes and antimicrobial organisms. Plant extracts exhibiting high α-glucosidase and lower 
α-amylase inhibitory activity are ideal for the treatment of DM and infections related to DM 
with possible minimal side effects. This enzyme activity combination prevents simultaneous 
inhibition of both enzymes, which could lead to abnormal bacterial fermentation of raw 
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carbohydrates in the gut causing side effects such as flatulence, and diarrhoea (SEETALOO 
et al., 2019). 
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CHAPTER FOUR: EVALUATION OF MUTAGENICITY OF 
SELECTED PLANT EXTRACTS 
4.1 Introduction   
 
Medicinal plants have been utilized since time immemorial to treat numerous ailments 
including degenerative disorders such as diabetes mellitus (DM) (SOFOWORA et al., 2013). 
These plants still form an integral part of primary health care in many developing countries 
including South Africa (ELGORASHI et al., 2003; AREMU et al., 2013). Most individuals 
in developing countries prefer using medicinal plants over western or synthetic medicine 
(GURUB-FAKIM, 2006). In South Africa particularly, about 60% of the population consult 
traditional healers with regards to either psychological, physical or metabolic disorders such as 
DM (ELGORASHI et al., 2003). Presently there is a societal perception that natural products 
possess little to no toxicity while western medicinal products are believed to be toxic and cause 
undesirable side effects (MATTANA et al., 2014). Often medicinal plants are consumed 
without any proof or knowledge about their safety (MATTANA et al., 2014; VARGAS et al., 
1991). The side effects of commonly used medicinal plants are not thoroughly recorded in the 
literature (ELGORASHI et al., 2003), nonetheless, the World Health Organisation (WHO) 
has encouraged developing countries to supplement their health programs with complementary 
and alternative medicines (CAM), such as traditional medicine under the condition that they 
are non-toxic (AKINTONWA et al., 2009; HONG and LYU, 2011). 
Generally, plants are known to produce many secondary metabolites. These chemicals may be 
produced as a defence mechanism in response to environmental stimuli such as stress, infection 
or insect and herbivore attack (CUZZOLIN et al., 2006). However, these secondary 
metabolites are vital sources of diverse chemical compounds with exceptional medicinal 
properties (ARAUJO et al., 2015).  
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ARAUJO et al. (2015) defined genotoxicity as ‘the ability to interact with DNA and/or the 
cellular apparatus that regulates the fidelity of the genome’ and according to SHAH (2012) 
this could eventually induce mutations in several body systems.  As humans, we are 
continuously exposed to many chemical substances present in our environments which have 
the potential of being mutagenic (BHATTACHARYA, 2011). These mutagens can be either 
chemical or physical agents capable of altering the genetic makeup and/or accelerate the 
occurrence of mutations (MORTELMANS and ZEIGER, 2000). In living organisms, 
cellular system mutations may cause irreversible metabolic defects which may instigate 
morbidity and mortality (BHATTACHARYA, 2011). 
Numerous researchers have reported on the potential mutagenic and antimutagenic properties 
of some medicinal plants (FERNANDES and VARGAS, 2003; VERSCHAEVE et al., 2004; 
VERSCHAEVE and VAN STADEN, 2008). Green plants are known to be a major source of 
antimutagens and organic toxic agents which may become cytotoxic and genotoxic if used over 
lengthy periods of time (MATTANA et al., 2014; PLEWA and WAGNER, 1993). 
ELGORASHI et al. (2003), further emphasised concern over potential mutagenicity posed by 
the long term use of medicinal plants since it has been discovered that certain plants which are 
used as food and medicine have had mutagenic effects through in vitro screening assays. Some 
chemical substances found in medicinal plants have been identified to be potentially toxic, thus 
presenting genotoxic activities (DE SA´ FERREIRA and VARGAS, 1999). There is an 
increase in awareness of the poor quality and lack of scientific evidence with regards to the 
safety of plant products (ARAUJO et al., 2015). A study by DE SÁ FERREIRA and 
VARGAS (1999) displayed possible toxicity and carcinogenic effects of a number of 
compounds found in some studied medicinal plants. A wide variety of natural mutagens and 
carcinogens are present in the human diet as a result of several environmental factors (i.e 
ultraviolet light or radon gas) (VARGAS et al., 1991). Moreover, several workers have also 
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demonstrated the direct relationship between carcinogenicity and mutagenicity (BARTSCH 
and TOMATIS, 1983; JONES and RICHARDSON, 1981). Therefore, as a means to ensure 
the safety of medicinal plants, it is important to screen the plants for their mutagenic potential 
(VERSCHAEVE and VAN STADEN, 2008). 
Due to their low cost, high specificity and speed, techniques involving in vitro trials which 
evaluate cytotoxicity and mutagenicity are being employed more frequently as alternatives to 
animal toxicity tests (ASENSIO et al., 2007). A bacterial reverse mutation test requiring 
strains of either Salmonella typhimurium or Escherichia coli to detect point mutations of DNA 
is employed to screen for mutagenic activities in plant extracts (ARAUJO et al., 2015). This 
test detects mutation through reverse mutations that exist in the test strains, thus restoring the 
performance of the bacteria to produce essential amino acids. Furthermore, the revertant 
bacteria is detected by their capability to grow without supplied amino acids (OECD, 1997). 
The Ames test is a common and low cost bacterial mutagenicity test, widely employed to detect 
gene mutation by plant extracts using a common bacterial strain S. typhimurium 
(MORTELMANS and ZEIGER, 2000; ARAUJO et al., 2015). This method involves 
reverse His- → His+ mutations that can be observed through the plating of S. typhimurium 
grown in a histidine deprived growth medium (MORTELMANS and ZEIGER, 2000; 
VERSCHAEVE and VAN STADEN, 2008). The use of different S. typhimurium bacterial 
strains allows for identification of the type of mutations occurring. For this reason, the present 
experiment was designed to screen the safety of some plant extracts demonstrating good 
antidiabetic inhibitory activities.  
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4.2 Materials and Methods   
 
4.2.1 Preparation of plant extracts 
 
Plant extracts were prepared as described in Chapter 2, section 2.2.2. The extracts were selected 
based on their complementary antidiabetic activity (high α-glucosidase and mild α-amylase 
inhibitory activity). The organic (ACE and DCM) extracts were dissolved with 50% DMSO to 
10 mg/mL. The extract solutions were filter-sterilized using 0.22 μm Millipore filter tips. The 
filter-sterilized stock solutions were used to prepare working solutions (5000 μg/mL, 500 
μg/mL, and 50 μg/mL) by simple dilutions with 50% DMSO.  
4.2.2 Ames assay performed on selected plant extracts  
 
The S. typhimurium microsome assay was used to evaluate mutagenicity of medicinal plant 
extracts that displayed good antidiabetic activities using tester strains TA102 and TA1535 
without metabolic activation (MARON and AMES, 1983; MORTELMANS and ZEIGER, 
2000). The TA1535 strain, as a result of the substitution of a leucine (GAG/CTC) by a proline 
(GGG/CCC), contains a hisG46 marker. Mutations that result in base pair substitution at the 
GC site can revert the hisG46 mutation to a wild type. The TA102 strain has an AT base pair 
at the hisG428 mutant site. Mutagens causing oxidative damage can revert hisG428 back to the 
wild type (NDHLALA et al., 2010).  
The different bacterial tester strains were inoculated and kept overnight in 10 mL Oxoid 
nutrient broth No. 2 for 16 h at 37 °C. The top agar supplemented with 0.5 mM histidine and 
biotin (100 mL of top agar and 10 mL biotin/histidine) was melted and kept in a 50 °C water 
bath throughout the preparation to prevent the agar from solidifying. One hundred microlitres 
of plant extract were dispensed into the allocated sterile tubes and further diluted with 500 μL 
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of phosphate buffer (adjusted to pH 7.4). To each test tube containing the extract mixture, the 
overnight bacterial cultures (100 μL) were added. Successively, 2 mL of enriched top agar was 
added to each tube and the resulting mixture was immediately mixed by vortexing and poured 
onto minimal plates and allowed to solidify and then incubated in an inverted position at 37 °C 
for 48 h. The tumorigenic chemical 4-nitroquinoline–N-oxide (4NQO) (2 μg/mL) was used as 
a positive control for the experiment whereas sterile distilled water was used as a negative 
control. After 48 h of incubation, the number of bacterial colonies were counted using a colony 
counter. 
4.3 Results and Discussion  
 
The Ames test was performed to determine and validate the potential genetic mutation that 
may be caused by the plant extracts, in the absence of the S9 metabolic activation which 
detects indirect mutations. The exogenous metabolic activation system (S9 mix) was 
unobtainable due to import challenges and so the indirect analysis of mutation by the plant 
extracts could not be carried out. The results of revertant colonies are presented in Table 4.1. 
ZEIGER (2001) explains that in order for a substance to be recognized as mutagenic it 
should produce a positive response with or without metabolic activation in any single 
bacterial strain. 
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Number of revertant colonies: mean values of three triplicates. ACE= acetone, DCM= 
dichloromethane, 4NQO= 4-nitroquinoline–N-oxide. The assay was repeated two times. 
 
According to VERSCHAEVE and VAN STADEN (2008) a plant extract may also be 
considered mutagenic if (a) there is an observed dose dependant increase in number of 
revertants, (b) the number of revertants is equal to or greater than two times the negative 
control. The organic plant extracts of B. natalensis, K. africana and S. birrea under 
investigation were not mutagenic against both the tester strains (TA102 and TA1535) without 
the S9 metabolic activation. The observed antimutagenic activity by these extracts means that 
the number of revertant colonies did not fulfil the criteria for mutagenicity. Extracts may be 
Plant species Plant part Solvent Concentration 
(μg/mL) 
             TA strains 
    TA102 TA1535 
Bulbine natalensis  Roots DCM 5000 90.67±9.06 8.00±0.67 
   500 114.00±6.51 8.67±2.08 
   50 83.67±3.18 7.33±1.33 
  ACE 5000 118.67±22.59 11.00±2.78 
   500 187.67±9.84 7.00±1.00 
   50 76.33±3.18 10.00±2.52 
Kigelia africana Fruit ACE 5000 124.33±27.14 7.33±1.20 
   500 101.00±6.00 8.00±1.15 
   50 104.00±5.03 4.00±2.08 
Sclerocarya birrea Stem bark ACE 5000 125.67±47.67 7.33±1.33 
   500 116.67±5.36 7.00±1.53 
   50 97.67±3.76 6.33±0.67 
4NQO   2 237.00±25.77 210.67±15.53 
Water   - 115.00±8.39 6.00±2.52 
Table 4. 1: The rate of mutagenic activity of selected plant extracts. 
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classified as toxic, should the number of revertant colonies be drastically less than the negative 
control (spontaneous reversion) (NDHLALA et al., 2010). In addition, no significant dose-
dependent increase in the number of revertants by non-mutagenic extracts was observed. The 
non-mutagenic activities of the plant extracts may be due to organic compounds such as tannins 
and flavonoids which are reported to possess anti-mutagenic and anti-carcinogenic properties 
linked to oxidative activities that are involved in mutagenic deactivation (HORN and 
VARGAS, 2003; KADA et al., 1985).  
Non-mutagenic activity using the Ames test by most of the plant extracts against S. 
typhimurium as observed in the experiment is a positive step in establishing the partial safety 
of plant extracts. However, the negative response only confirms anti-mutagenicity towards the 
specific bacterial strains as well as their tested genetic endpoints and not their complete 
toxicology (REID et al., 2006).  
 
However, with regards to the stem bark extract (ACE) of S. birrea, the extract may be identified 
as a weak mutagen, as the number of revertant colonies is not two times the background number 
of colonies but demonstrated a slight dose dependant increase in the number of revertant 
colonies (MORTELMANS and ZEIGER, 2000). Despite the significant pharmacology and 
phytochemistry of the stem bark of the S. birrea observed in this study, several authors 
withdrew their focus on the use of this plant as an antidiabetic traditional medicine 
(OJEWOLE, 2003; VAN DE VENTER et al., 2008). This is largely due to reports by 
OJEWOLE (2003) stating that previously identified chemical compounds found in the bark 
extracts may be lethal to mammals. VAN DE VENTER et al. (2008), who demonstrated 
toxicity effects of the plant extracts in cultured adipocytes and hepatocytes, further 
corroborated this finding. The extract of S. birrea stem bark has displayed high quantities of 
polyphenolic contents (Figure 2.2, 2.3 and 2.4). Though secondary metabolites including 
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flavonoids, terpenoids and tannins among others, have been reported to possess anti-mutagenic 
properties (BHATTACHARYA, 2011), some mutagenic extracts have been linked to tannins 
and flavones as corroborated by VARGAS et al. (1991). According to MORTON (1980), high 
consumption of tannins and other anthocyanin’s of plant material could lead to oesophageal 
cancer. Mutagenic agents may potentially cause fertility issues, generational mutations and 
induce cancer due to impairment of the germ line (AREMU et al., 2013; MORTELMANS 
and ZEIGER, 2000). 
 
 
4.4 Conclusions 
 
It should be a priority to evaluate the potential risks of consuming medicinal plants before they 
can be utilised as remedies for various ailments. The S9 metabolic activation should also be 
performed to further establish the indirect mutagenesis of the plant extract. 
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CHAPTER FIVE: GENERAL CONCLUSIONS 
 
The widespread scourge of non-communicable diseases like diabetes mellitus (DM) is a cause 
for concern. Despite the multitude of steps taken to improve the understanding and 
management of the disease and its related complications, DM still proves to be difficult to 
control and continues to affect millions of people worldwide, at an alarming rate. The World 
Health Organisation reported that diabetes is one of the major causes of morbidity and mortality 
of our era (WHO, 2016). Synthetic medicines such as acarbose or insulin have been developed 
for the treatment of diabetes, however, a definite cure is yet to be discovered. Due to 
undesirable side effects (i.e. flatulence or abdominal pains) (NASRI et al., 2015), caused by 
these synthetic medicines and often inaccessible health facilities, patients resort to the use of 
alternative therapies like indigenous medicinal plants and herbal medicines, which are believed 
to pose minimal side effects. Four traditional medicinal plants used in South Africa to treat 
diabetes were selected and subjected to biological screening to validate and assess their 
pharmacological efficacy, phytochemical composition and safety. 
Antidiabetic inhibitory screening of plant extracts demonstrated a wide range of inhibitory 
activities towards the carbohydrate digesting enzymes (Figure 3.1 and 3.2). Moderate (30-49%) 
α-amylase inhibitory activity was displayed by extracts including the PE and ACE extracts of 
leaves of K. africana, ACE extracts of roots and PE leaf of B. natalensis, water extract of L. 
leonurus as well as DCM and ACE extracts of the stem bark of S. birrea. On the other hand, 
extracts exhibiting potent α-glucosidase activity consisted of the DCM and ACE extracts of 
roots of B. natalensis, ACE extracts of leaves of B. natalensis and ACE extracts of fruit of K. 
africana as well as ACE and water extracts of the S. birrea stem bark. These results 
demonstrate appreciable complementary inhibitory activities and they are considered desirable 
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and effective hypoglycaemic agents which could potentially preserve the integrity of pancreatic 
β-cells, thus reducing postprandial hyperglycemia.  
DM compromises the immune system of patients and as a result they fall prey to pathogenic 
fungal and bacterial infections. Hence, the plant extracts were screened for antimicrobial 
(antibacterial and antifungal) activities. The extracts generally displayed good antimicrobial 
activity against test organisms, however, these extracts displayed more activity towards the 
Gram-positive strains. The DCM and ACE extracts of roots and the PE and DCM extracts of 
leaves of B. natalensis, the ACE and water extracts of fruit and the PE, DCM and ACE of the 
leaf extracts of K. africana, leaves of L. leonurus (ACE and DCM), and the ACE and water 
extracts of S. birrea stem bark demonstrated noteworthy antibacterial activity (MIC < 1 
mg/mL) against some of the tested bacterial strains. The water extracts mostly displayed 
minimal antimicrobial activities (MIC > 1 mg/mL) but extracts of S. birrea (0.31 and 0.63 
mg/mL) and fruit of K. africana (0.63 mg/mL) displayed the highest antibacterial activity. The 
plant extracts demonstrated maximum antifungal activity, but roots of B. natalensis (DCM) 
and leaves of L. leonurus (PE and ACE) and S. birrea (ACE and water) revealed high antifungal 
activity. Overall antimicrobial activities were observed more in organic plant extracts than 
water extracts, owing to the versatility of the solvents ability of extract varied compounds. 
Oxidative stress plays a major role in the onset of diabetes and associated complications. 
Therefore, the plant extracts were subjected to antioxidant (β-Carotene; DPPH; H2O2 and 
FRAP) and phytochemical screening. The extracts generally demonstrated high scavenging 
abilities for free radicals. The ability of the plant extracts to delay β-Carotene bleaching (Table 
2.2) was displayed by the ACE (86.49 %) extracts of roots of B. natalensis, ACE (94.58 %) 
and water (84.81 %) extracts of S. birrea, exhibiting ORR values lower than the reference drug 
BHT (0.18). The highest DPPH and hydrogen peroxide free radical scavenging activities 
(Table 2.3) were as a result of the ACE extract of fruit of K. africana (IC50 = 0.01 mg/mL) 
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which was superior to the reference drugs (ASC and BHT). The PE extracts of fruit of K. 
africana, DCM extracts of leaves of L. leonurus as well as the ACE and water extracts of the 
stem bark of S. birrea showed strong ferric reducing potentials. Secondary metabolites are 
reported to possess good pharmacological activities, forming a basis for the demonstrated 
biological activities of the plant extracts investigated. The preliminary screening (Table 2.4) of 
secondary metabolites of the different plant extracts displayed both the presence and absence 
of certain chemical compounds. All the methanolic extracts displayed the presence of 
flavonoids, carbohydrates and alkaloids. The extracts were further quantified for specific 
secondary compounds (total phenolic content, condensed tannins and flavonoids) which were 
demonstrated at different levels (Figures 2.2, 2.3 and 2.4). The S. birrea stem bark 
demonstrated very high polyphenolic contents as compared to the other extracts. Due to the 
groups of secondary metabolites identified, the plant species have demonstrated their potential 
to serve as natural antidiabetic medicines but also to serve as antimicrobial and antioxidant 
agents. These findings validate the traditional use of the selected plant species as antidiabetic 
agents and displayed their potentials to also prevent oxidative damage to cells. 
The safety of consumed plant materials should be evaluated to ensure that the material is not 
toxic. The Ames test was performed to assess the mutagenic potential of the most active 
antidiabetic extracts. The extracts did not show mutagenic activity, but the ACE extract of S. 
birrea demonstrated weak mutagenic behaviour towards both the TA102 and TA1535 bacterial 
strains. The negative mutagenic response by some of the plant extracts requires further 
evaluation with other test strains (TA97, 98, 100, and 1537), including the S9 exogenous 
metabolic activation to establish accurate and conclusive results of their non-mutagenicity.  
 
 
 
90 
 
Recommendation 
  
Findings of this research indicated that the stem bark of S. birrea had notable pharmacological 
properties, however the plant extracts (ACE) also demonstrated some weak mutagenic 
attributes suggesting that it is ill-advised for long term usage. This information should be 
incorporated into the indigenous knowledge systems (IKS) in order for locals to be aware of 
the health risks associated with the long term use of S. birrea.  
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